Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2014

EVALUATION OF THE PHYSIOLOGICAL EFFECTS OF REDUCED
HYDROXOCOBALAMIN ON ACUTE CARBON MONOXIDE
TOXICITY
Alden Newcomb
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/3560

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

© Alden Newcomb 2014
All Rights Reserved

i

EVALUATION OF THE PHYSIOLOGICAL EFFECTS OF REDUCED
HYDROXOCOBALAMIN ON ACUTE CARBON MONOXIDE TOXICITY
A thesis submitted in partial fulfillment for the degree of Master of Science in Physiology
& Biophysics at Virginia Commonwealth University

By

ALDEN H. NEWCOMB
Bachelor of Science, Biochemistry, Virginia Polytechnic Institute and State University,
2012
Director: DR. BRUCE SPIESS, MD, FAHA
DIRECTOR VIRGINIA COMMONWEALTH UNIVERISTY REANIMATION SHOCK
CENTER, DEPARTMENT OF ANESTHESIOLOGY, VCU SCHOOL OF MEDICINE

Virginia Commonwealth University
Richmond, VA
July, 2014

ii

Acknowledgements

I would like to thank Dr. Bruce Spiess for granting me the incredible opportunity
to become a part of the VCURES family and providing me with the support,
encouragement, and funds to bring this project to fruition. Additional heartfelt thanks go
out to Dr. Christina Marmarou and Dr. Brandon Wills, for their tireless support and
encouragement through this process. Thanks to Dr. Penny Reynolds, Dr. Jiepei Zhu,
and Mr. Brian Berger for their willingness to share their endless expertise and answer
my equally endless questions. I feel truly blessed to be a part of the VCURES team and
could not have asked for more brilliant and supportive educators. From the bottom of
my heart, thank you. I also cannot possibly articulate how grateful I am for the
continuous support from my family. Without the emotional and financial support from my
mother, grandmother, and sister, I know that I couldn’t have made it this far. Finally, I
would like to thank and dedicate this work to my friend, mentor and guardian angel, Dr.
Cheryl Haas, who will forever motivate me.

iii

TABLE OF CONTENTS
LIST OF FIGURES .......................................................................................................... vi
LIST OF TABLES ........................................................................................................... vii
LIST OF ABBREVIATIONS ............................................................................................ viii
ABSTRACT ................................................................................................................... xiv
1. INTRODUCTION AND BACKGROUND.........................................................................
1.1 Carbon Monoxide – A Global Health Threat ........................................................... 1
1.2 Carboxyhemoglobin ................................................................................................ 4
1.3 Effects of CO on the Vascular & Cardiopulmonary Systems ....................................
1.3.1 CO & The Vasculature ..................................................................................... 8
1.3.2 CO-Induced Myocardial Damage ..................................................................... 9
1.3.3 CO-Induced Myocardial Damage – Cellular Toxicity ..................................... 10
1.3.4 The Respiratory System & Blood Chemistry in CO Poisoning ....................... 13
1.4 Effects of CO on the Brain ........................................................................................
1.4.1 Acute Pathophysiology ................................................................................... 15
1.4.2 Delayed Pathophysiology ............................................................................... 17
1.5 Clinical Presentation, Diagnosis, & Treatment of CO Poisoning ..............................
1.5.1 Clinical Presentation ...................................................................................... 18
1.5.2 Diagnostic Workup & Common Findings ....................................................... 19
1.5.3 Current Treatment Modalities & Controversies .............................................. 20
1.6 A Potential Antidote ..................................................................................................
1.6.1 Hydroxocobalamin ......................................................................................... 25

iv
1.6.2 Reduced Hydroxocobalamin & CO ................................................................ 26
1.7 Hypotheses & Specific Aims ................................................................................. 27
1.8 Basic Approach .........................................................................................................
1.8.1 Non-Survival Surgery ..................................................................................... 28
1.8.2 Brain Tissue Oxygen Tension Monitoring ...................................................... 30
1.9 Summary of Findings ............................................................................................ 32
2. MATERIALS & METHODS .............................................................................................
2.1 Materials ............................................................................................................... 34
2.2 Production of Reduced Hydroxocobalamin .......................................................... 37
2.3 Animals & Ethics Statement ................................................................................. 38
2.4 Non-Survival Surgical Proceudre ..............................................................................
2.4.1 Experimental Group Assignment & Procedural Preparation .......................... 38
2.4.2 Femoral Artery Cannulation ........................................................................... 39
2.4.3 Licox® Placement .......................................................................................... 41
2.4.4 Insult, Treatment, & Post-Treatment Monitoring ............................................ 44
2.5 Statistical Analysis ................................................................................................ 46
3. RESULTS .......................................................................................................................
3.1 Brain Tissue Oxygen Tension Results .................................................................. 47
3.2 Mean Arterial Pressure Results ............................................................................ 53
3.3 Arterial Blood Gas Results .................................................................................... 59
3.4 Respiratory Rate Results ...................................................................................... 63
4. DISCUSSION .................................................................................................................
4.1 CO Poisoning, Perfusion, & Oxygenation ............................................................ 66

v
4.2 Post-Exposure & Treatment ................................................................................. 74
4.3 Limitations & Sources of Error .............................................................................. 78
4.4 Future Work .......................................................................................................... 79
4.5 Summary .............................................................................................................. 80
4.4 Conclusion ............................................................................................................ 81
Bibliography .................................................................................................................... 83
Vita ................................................................................................................................. 96

vi

LIST OF FIGURES
Figure 1: Schematic of %COHb Changes in Maternal and Fetal Hb ............................... 5
Figure 2: Overview of CO-Mediated Pathophysiology ..................................................... 7
Figure 3: Pathophysiology of CO-Mediated Cardiotoxicity ............................................. 12
Figure 4: Visual Representation of Surgical Procedure Timeline .................................. 29
Figure 5: Licox® Brain Tissue Oxygen Tension Electrode ............................................. 31
Figure 6: Surigcal Equipment for Arterial Line Placement .............................................. 35
Figure 7: Surgical Equipment for Licox® Electrode Placement & Monitoring ................ 36
Figure 8: Bilateral Craniotomy Holes .............................................................................. 43
Figure 9: Licox® PbtO2 Electrode Preparation & Placement ......................................... 44
Figure 10: Mean PbtO2 and Standard Deviations of the Mean Over Time..................... 50
Figure 11: Individual PbtO2 Trajectories by Experimental Group .............................. 51-52
Figure 12: Mean MAP and Standard Deviations of the Mean Over Time ...................... 57
Figure 13: Indvidual MAP Trajectories by Experimental Group ................................ 58-59
Figure 14: Mean Respiratory Rate and Standard Deviations of the Mean Over Time ... 65
Figure 15: Correlation of PbtO2 and MAP during CO Exposure ..................................... 69
Figure 16: Correlation of PbtO2 with MAP – Hemphill et al. ........................................... 70
Figure 17: Overlay of Pre- & Post-Treatment PbtO2/MAP.............................................. 76
Figure 18: Mean PbtO2/MAP for all Groups and Times.................................................. 77

vii

LIST OF TABLES
Table 1: Experimental Exposure-Treatment Groups and Sample Sizes ........................ 38
Table 2: B12r Dosing Protocol ....................................................................................... 45
Table 3: Mean PbtO2 Values and Standard Deviations of the Mean.............................. 12
Table 4: Summary Statistical Data for PbtO2 Analysis .................................................. 49
Table 5: Mean MAP Values and Standard Deviations of the Mean ............................... 55
Table 6: Summary Statistical Data for MAP Analysis .................................................... 56
Table 7: Mean ABG Parameter Values and Standard Deviations of the Mean .............. 62
Table 8: Summary Statistical Data for ABG Parameter Analysis ................................... 63
Table 9: Mean Respiratory Rate and Standard Deviations of the Mean ........................ 64
Table 10: Summary Statistical Data for Respiratory Rate Analysis ............................... 64

	
  

viii

LIST OF ABBREVIATIONS
AA – Ascorbic acid, ascorbate, or vitamin C. Reducing agent used to reduce
hydroxocobalamin.
ALS – Advanced Life Support. An abbreviation used to refer to the level of training of an
emergency medical services provider. ALS providers include EMT-Intermediates and
Paramedics. These providers are capable of performing procedures above that of an
emergency medical technician including intravenous drug administration, endtracheal
intubation, and cardiac monitoring.
ATP – Adenosine Triphosphate. A high-energy nucleoside triphosphate that serves as
an energy source for intracellular processes.
B12 – Hydroxocobalamin, or vitamin B12.
B12r – Reduced form of hydroxocobalamin formed when AA is mixed with B12 in
proper proportions.
BKCa – Large (Big) Conductance Calcium-Activated Potassium Channel. Potassium
channel characterized by large conductance of potassium that are essential for smooth
muscle tone and neuronal excitability.
BLS – Basic Life Support. Refers to the lowest and most basic level of training for
emergency medical technicians. BLS providers are only able to provide non-invasive
treatments including oral medication administration and oxygen administration.
CaO2 – Arterial Content of Oxygen. Calculated as:
𝐶! 𝑂! = 𝑐𝑡𝐻𝑏×1.34×𝑆! 𝑂! + 0.003×𝑝! 𝑂!

ix

CvO2 – Venous Content of Oxygen. Calculated as:
𝐶! 𝑂! = 𝑐𝑡𝐻𝑏×1.34×𝑆! 𝑂! + 0.003×𝑝! 𝑂!
CBF – Cerebral Blood Flow. The amount of blood flowing into the brain, calculated as
the difference between mean arterial pressure and intracranial pressure.
cGMP – Cyclic Guanosine Monophosphate. A cyclic nucleotide formed from guanosine
triphosphate that functions as a key second messenger in many intracellular processes.
CMRO2 – Cerebral Oxygen Consumption Rate. The amount of oxygen consumed by
the brain. Calculated as: 𝐶𝑀𝑅𝑂! = 𝐶𝐵𝐹(𝐶! 𝑂! − 𝐶! 𝑂! )
CO – Carbon monoxide
CO2 – Carbon dioxide
COHb – Carboxyhemoglobin. Hemoglobin bound to carbon monoxide in place of, or in
addition to oxygen.
COHb% - Percentage of carboxyhemoglobin.
ctHb – Total concentration of hemoglobin. Amount of hemoglobin in a blood sample,
typically expressed in g/dL.
DNS – Delayed Neurological Sequelae. A term used to refer to the lasting neurological
effects demonstrated following resolution of carbon monoxide exposure symptoms. Also
referred to as “Prolonged Neurological Sequelae,” or PNS.
DO2 – Oxygen Delivery. Refers to the amount of oxygen delivered to the whole body or
specific organ. In the context of the brain, it is calculated as 𝐷𝑂! = 𝐶𝐵𝐹×𝐶! 𝑂!
ED – Emergency Department. Hospital department responsible for examination and
treatment of patients experiencing a medical emergency.

x
EMS – Emergency Medical Services. Refers to systems in place across the United
States and world that provide ambulance-based emergency medical care. EMS
providers are trained at the emergency medical technician level or higher.
EMT – Emergency Medical Technician. An abbreviation used to refer to emergency
responders trained to provide BLS pre-hospital medical care.
ER – Emergency Room. Used interchangeably with ED to refer to hospital emergency
departments.
FCOHb – Fraction of Carboxyhemoglobin. An alternative abbreviation for %COHb.
GTP – Guanosine Triphosphate. A high-energy purine nucleoside triphosphate that
serves as an energy source for intracellular processes.
HEMS – Helicopter EMS. The abbreviation used to refer to helicopter-based EMS care,
which typically offers significantly more advanced care and monitoring than ground
ambulances.
Hb – Hemoglobin. The protein responsible for transport of diatomic oxygen within the
body. It is comprised of four subunits, each of which contain a porphyrin ring with a
central ferrous iron core. Each subunit is capable of binding and transporting a single
diatomic oxygen molecule.
HBO – Hyperbaric Oxygen Therapy. Abbreviation used to describe the process of using
a sealed chamber to deliver high-concentration oxygen at 2-3 times above normal
atmospheric pressure to provide an increased partial pressure of oxygen in order to
drive off carbon monoxide from hemoglobin in CO poisoned patients. Considered the
current gold standard in CO poisoning treatment.

xi
HCO3- - Bicarbonate ion. The anion of carbonic acid. Can refer to the ion itself or the
calculated value of bicarbonate in a blood sample, expressed as mEq/L.
HO – Heme-Oxygenase Enzyme responsible for endogenous CO production via
degradation of heme into protoporhyrin IX.
HVAC – Heating, Ventilation, and Air Conditioning. Used to refer to systems that control
and supply indoor temperature control, ventilation, and air quality.
IP – Intraperitoneal. Administration of a drug via injection into the abdominal cavity for
absorption by the peritoneum.
IRB – Institutional Review Board. The university department responsible for oversight
and approval of all projects involving the use of human subjects in research.
IV – Intravenous. Administration of a drug via injection into the venous system.
MAC – Minimum Alveolar Concentration. A relative concentration of anesthetic gas
required to sedate 50% of a given species or population to an adequate anesthetic
plane to tolerate surgical pain
NBO – Normobaric Oxygen Therapy. The application of high-concentration oxygen to
patients at normal atmospheric.
NO – Nitric Oxide. An endogenous gaseous signaling molecule that plays an important
role in vascular smooth muscle tone.
NS – Normal Saline. An isotonic 0.9% saline solution.
O2 – Diatomic Oxygen.
O2Hb – Oxyhemoglobin. Hemoglobin bound to oxygen.
OHCbl – Hydroxocobalamin. A form of vitamin B12 containing a hydroxyl group bound
to the upper axial ligand binding site. Refers specifically to the non-reduced form.

xii
OSHA – Occupational Health and Safety Administration. The government agency
responsible for establishing guidelines for safe workplace environments.
PbO2 – Brain Tissue Oxygen Tension. A measurement of oxygen tension within brain
tissue as measured by Licox® Clark-type polarographic electrode, expressed in mmHg.
pCO2 – Partial Pressure of Carbon Dioxide. A measure of the pressure of dissolved
carbon dioxide within a blood sample relative to the pressure of other gases within the
same sample. Expressed in mmHg.
pH – A measure of the concentration of hydrogen atoms in a solution on a logarithmic
scale.
pO2 – Partial Pressure of Oxygen. A measure of the pressure of dissolved oxygen
within a blood sample relative to the pressure of other gases within the sample.
Expressed in mmHg.
PNS – Prolonged Neurological Sequelae. See DNS.
PPM – Parts Per Million.
Q – Cardiac Output. The product of stroke volume and heart rate. Commonly
abbreviated CO, but substituted for the physiological abbreviation to avoid confusion
with carbon monoxide.
RBC – Red Blood Cell.
ROS – Reactive Oxygen Species. Commonly known as “free radicals.” Produced as a
natural byproduct of respiration, accumulation of these compounds is cytotoxic.
RR – Respiration Rate. The number of respiratory cycles in a given time frame.

xiii
RRS – Raman Resonance Spectroscopy. An analytical technique that uses
monochromatic laser light directed onto a sample to identify chemical components.
Used to verify the production of B12r in B12+AA mixtures.
sGC – Soluble Guanylyl Cyclase. A heme-containing protein responsible for the
conversion of GTP to cGMP.
T1/2 – Half-life. Time required for a compound to decay to half of the original
concentration.
VO2 – Oxygen consumption. Refers to whole body oxygen consumption in the context
of this paper. Calculated according to the Fick equation: 𝑉𝑂! = 𝑄×(𝐶! 𝑂! − 𝐶! 𝑂! )

Abstract
EVALUATION OF THE PHYSIOLOGICAL EFFECTS OF REDUCED
HYDROXOCOBALAMIN ON ACUTE CARBON MONOXIDE TOXICITY
By: Alden H. Newcomb, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Virginia Commonwealth University, 2014
Major Advisor: Dr. Bruce Spiess, MD, FAHA
Director, Virginia Commonwealth University Reanimation Shock Center
Affiliate Professor, Department of Physiology & Biophysics
Carbon monoxide (CO) poisoning represents a global health threat responsible for
hundreds of thousands of hospital visits and tens of thousands of deaths annually.
Oxygen therapy is the only current approved treatment for CO poisoning. Previous work
published in the 1970’s and research conducted in the VCURES lab group has
indicated that a reduced form of vitamin B12, hydroxocobalamin (B12r), can potentially
serve as an antidote for CO poisoning by converting CO bound to hemoglobin to carbon
dioxide (CO2) and mitigating the deleterious neurological effects of CO poisoning. For
the first time in documented literature we successfully used a Clark-type polarographic
oxygen-sensitive electrode to demonstrate CO-induced decreases in brain tissue
oxygen tension in anesthetized rats. Additionally, we demonstrated that B12r is capable
of rescuing this CO-induced hypoxia and hypotension within 15 minutes of
intraperitoneal administration with no adverse effects on blood chemistry.
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INTRODUCTION AND BACKGROUND
1.1 Carbon Monoxide Poisoning – A Global Health Threat
The toxic and fatal effects of carbon monoxide (CO) have been known for
thousands of years; ancient Greeks and Romans used the gas for execution purposes.
Known as “the silent killer” due to its lack of color, odor, or taste, CO forms from the
incomplete combustion of hydrocarbons and other carbon-containing compounds.1 The
Occupational Health and Safety Administration (OSHA) requires workplace atmospheric
CO concentrations to be less than 0.0035%, or 35 parts per million (ppm), indicating
how toxic CO truly is.2 Common sources of CO production include exhaust from internal
combustion engines, improperly ventilated gas appliances, malfunctioning HVAC
systems, and structure fires. Most recently, a faulty ventilation system in a New York
restaurant led to a mass CO exposure that caused one death and hospitalized dozens
of employees and restaurant patrons.3 In the United States alone between 2000 and
2009, non-fire related CO exposures accounted for over 15,000 emergency department
(ED) visits and over 500 deaths annually.4–6 The World Health Organization reported
over 140,000 non-fire related CO deaths in European member states from 1980-2008.7
When fire-related CO exposures are accounted for, these numbers increase drastically.
Each year, a reported 310,000-670,000 persons are exposed to structure fire smoke
and 20,000-23,000 die from smoke inhalation in the United States alone.8 Structure fire
smoke can contain CO levels of greater than 70,000 parts per million (ppm) in an
enclosed room.9 The actual number of annual carbon monoxide exposures and deaths
is assumed to be much higher than the reported numbers because CO exposure
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symptoms are often mistaken for benign pathologies like acute viral illnesses, acute
anxiety, or clinical depression.10 Across the globe, carbon monoxide is thought to
account for over 50% of deaths by poisoning.10,11
Incidences of CO poisoning vary seasonally in temperate climates. Cold seasons
are often associated with higher numbers of CO exposures due to improperly ventilated
hydrocarbon-powered heating appliances.10 Natural disasters such as hurricanes,
tornadoes, and snowstorms also bring about an increase in CO poisonings due to the
use of generators and other fossil fuel-powered appliances indoors with poor ventilation.
Between 1991 and 2009, there were 1888 reported cases of disaster-related CO
exposure with 75 fatalities.12 In the two weeks following Hurricane Sandy in 2012, there
were 437 CO exposures reported to 911 call centers in New York City alone due to
indoor grilling and indoor use of gasoline generators.13 Gasoline powered generators
are the most common culprit behind hurricane and tornado related CO exposures;
vehicle exhaust is the most common cause of CO exposures related to snowstorms.14–
16

Countries in tropical climates, particularly developing countries, have reported CO

exposures resulting from the use of indoor charcoal cooking devices.17 Gas geysers, a
type of gas-powered water heater popular in India, have been linked to multiple deaths
and CO poisonings. However, the true number of CO-related deaths and exposures in
India is unknown due to improper reporting of suspected cases.18,19
The abovementioned CO poisonings and deaths do not account for intentional
exposures, that is, attempted and successful suicides. Intentional CO exposures
account for over 15,000 ED visits annually and two thirds of all CO-related deaths in the
United States.20 In New Zealand, over 60% of the reported 1,302 intentional poisoning
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deaths between 1999 and 2008 were due to CO inhalation.21 Suicide by intentional CO
inhalation is common across the globe, with vehicle exhaust and charcoal smoke as the
two most common CO sources.22–34 Intentional vehicle exhaust exposures can take
place both indoors and outdoors. Indoor exposures generally involve idling a vehicle in
an enclosed space, often a garage, with the vehicle windows down and garage door
shut. Outdoor exhaust inhalations require slightly more creative methods – a vacuum
hose or similar tubing is run from the vehicle tailpipe into the passenger compartment of
the automobile and exhaust fumes are allowed to accumulate within the cabin. Similar
methods have been reported in the United States, across Europe, and Asia.29,30,32,34,35
This method of intentional CO exposure has witnessed a decline over the past two
decades as modern catalytic converters can effectively scrub up to 99% of CO from
automobile exhaust.34
Although the incidence of vehicle exhausted-related CO exposures has declined,
the popularity of suicide by carbon monoxide has not. A simple Google search of
“commit suicide by carbon monoxide” yields multiple websites that provide detailed
instructions on how to do so.36,37 The most recent global trend in intentional CO
exposures involves burning charcoal inside of a small room, often a bathroom, that has
been sealed with duct tape.23 This method of suicide has gained popularity across the
world, but most notably so in Asian countries. Indoor charcoal burning accounted for
33.5% of all suicides in Taiwan in 2006.31,33 In Hong Kong, charcoal burning accounted
for 24.1% of suicides between 2002 and 2004.38 A startling Internet trend known as a
“suicide pact” has emerged in Japan and spread to China, in which strangers exchange
online messages vowing to commit suicide together. The cause of death in over 90% of
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these “internet suicides” in China and Japan was carbon monoxide poisoning due to
indoor charcoal burning.28,39

1.2 Carboxyhemoglobin
The central dogma of CO toxicity, herein referred to as the “hypoxic theory,” was
first described by Douglas and Haldane in the turn of the 20th century.40,41 Their work
has stood the test of time and is still taught in medical schools, nursing schools, and
allied health programs across the world. Carbon monoxide is nonpolar and therefore
lipophilic, diffusing rapidly across pulmonary epithelium when inhaled and binding tightly
to the central iron atom in the heme moiety of heme-containing proteins such as
hemoglobin (Hb), myoglobin, cytochromes, and NADH reductase.42 Binding of CO to Hb
forms carboxyhemoglobin (COHb), which is incapable of binding and transporting
oxygen (O2), thus causing a functional anemia by reducing the amount of
oxyhemoglobin (O2Hb). Carboxyhemoglobin formation also alters the confirmation of
hemoglobin, reducing its ability to release O2 to tissue. The increased oxygen affinity of
Hb in CO poisoning is known as the “Haldane effect.”43
This displacement of oxygen from hemoglobin and alteration of O2 release leads
to a decrease in tissue O2 delivery causing hypoxic injury, especially to organs that are
heavily oxygen dependent such as the brain and heart. Due to the high affinity of CO
for Hb, COHb exhibits a half-life (t1/2) of approximately 6 hours when an exposed patient
is removed from the environment containing CO and allowed to breathe ambient air.
Because of this long half-life, patients exposed to CO can potentially still suffer its
harmful effects hours after exposure.44–46 This holds especially true in pregnant patients
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due to the higher affinity of fetal Hb for both CO and O2. Thus, at equilibrium for a given
partial pressure of dissolved CO in blood, fetal COHb levels (%COHB) will be higher
than that of the mother and can continue to rise even while maternal %COHb drops.43 A
representative schematic of this phenomenon is depicted in Figure 1.

Figure 1 – Schematic of %COHb Changes in Maternal and Fetal Hb. Black
broken lines indicate %COHb steady-state equilibrium. Colored broken lines
represent immediate post-exposure treatment with normobaric O2. Colored dotted
lines represent immediate treatment with hyperbaric O2. Adapted from “Rapid
Elimination of CO from the Lungs: coming full circle 100 years on” by Fisher et al.,
2011, Experimental Physiology OA, 96:12, 1262-1269. Copyright 2011 by the
authors. Adapted with permission.
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The amount of COHb formed during CO inhalation varies with the concentration
of the inhaled gas, time exposed, cardiac output, respiratory rate, and tidal volume.
COHb formation continues during exposure until a steady-state equilibrium %COHb is
reached with the partial pressure of inhaled CO.40,41,46
Mammals form CO endogenously during the breakdown of heme via heme
oxygenase (HO) proteins. As such, humans will generally have a baseline %COHb from
0-3%. Smokers and people in urban environments can exhibit %COHb of greater than
10%.47 While it is generally accepted that high %COHb levels are associated with more
severe exposures and poor clinical outcomes, there is interestingly no correlation
between %COHb and prognosis.44,46,48–50 This phenomenon was first described by John
Haldane’s son in 1927, who reported that CO mortality was not related to the formation
of COHb.51 Patients presenting with a seemingly fatal %COHb can make complete
recoveries, just as those presenting with mildly increased %COHb may die or suffer
from lasting neurological and/or cardiac complications.44,46–48 The variances seen
between initial %COHb and prognosis are evidence that there is much more to CO
poisoning than COHb-dependent tissue hypoxia, and this is indeed true. A visual
representation of COHb-mediated pathophysiology and additional mechanisms to be
discussed in the proceeding sections is given in Figure 2.
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Figure 2 – Overview of CO-Mediated Pathophysiology. Adapted from: “Carbon
Monoxide Poisoning” by Guzman, J. Critical Care Clinics, 2012, 98:537-548. Copyright
2012, Elsevier. Adapted with permission.
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1.3 Effects of CO on the Vascular & Cardiopulmonary Systems
1.3.1 CO & Vasculature
Simple physics dictates that the formation of COHb requires a partial pressure of
dissolved CO in the bloodstream in order to form and stabilize the COHb complex. This
dissolved CO readily diffuses across endothelial membranes and into surrounding
tissue. CO exhibits potent vasodilatory effects in vascular tissue similar to those of nitric
oxide (NO) and hypotension is commonly seen in CO poisoned patients as a
result.42,44,52 Much like NO, CO is also produced endogenously. Endogenous CO forms
from the breakdown of heme via HO proteins that are expressed ubiquitously in the
body.53,54 Once synthesized by HO, CO binds and activates soluble guanylyl cyclase
(sGC), a heme-containing protein responsible for the conversion of guanosine
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Activation of sGC
increases cGMP concentration in vascular smooth muscle cells, which decreases
intracellular calcium (Ca2+) concentrations by blocking Ca2+ entry, blocks potassium
(K+) entry into the cell (thereby hyperpolarizing the membrane potential), and stimulates
myosin light chain phosphatase pathways resulting in smooth muscle relaxation and
vasodilation.53–55 NO production is also increased during exposure to low concentrations
(nanomolar levels) of CO. At low contentrations, CO binds to the heme moiety and
activates nitric oxide synthase (NOS) , the enzyme responsible for NO production. This
increase in NO production ceases at higher CO concentrations (mircomolar levels), at
which point CO actually inhibits NOS activity.42 CO also causes release of NO from

9
platelets and triggers platelet-neutrophil aggregation causing neutrophil diapedesis into
the endothelium and free radical-mediated endothelial injury.
In addition to the NO-cGMP-dependent pathway described above, CO has also
been shown to activate large-conductance calcium channels (BKCa). Although the
exact mechanism of the interaction between BKCa and CO remains elusive, multiple
studies have shown that activation of BKCa by CO results in a reduction of intracellular
Ca2+ via closing of voltage dependent Ca2+ channels, resulting in membrane
hyperpolarization and vasodilation.56,57
1.3.2 CO-Induced Myocardial Damage
Myocardial damage is common following moderate to severe CO exposure and
presents in approximately 35% of these patients.58 Chronic exposure to CO has been
shown to cause myocardial fibrosis and stunning; severe acute exposure is more
closely associated with lethal arrhythmias.52,58–60 Ventricular dysfunction and heart
failure have also been reported following CO exposure. These patients demonstrated a
strong negative correlation between left ventricular ejection fraction and %COHb (r=
-0.660) and duration of CO exposure (r= -0.630).58 Satran et al. reported that over one
in three patients hospitalized for CO exposure demonstrated elevated serum levels of
troponin I (TnI) and creatine-kinase MB fraction (CKMB), which are sensitive and
specific biological markers of cardiac injury.52,61 Fracasso and colleagues demonstrated
increased expression of two known markers of acute myocardial injury, fibronectin and
complement complex C5b-9, in the right ventricles of 26 out of 26 CO fatality victims.61
The toxicity exerted on cardiac tissue by CO is twofold and additive; decreased
O2 delivery causes a hypoxia/ischemia injury and a toxic injury forms from the direct
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cytotoxic effects of CO on cellular metabolism. This unique injury pattern is outlined in
Figure 2. CO-induced vasodilation causes a compensatory increase in heart rate,
cardiac output (Q), and contractility that has been well documented since the mid-19th
century.42,62 Coronary blood flow increases as well during CO exposure.59 Interestingly,
subendocardial blood flow only displays a marginal increase during CO exposure. This
indicates the possibility of subendocardial hypoperfusion playing a role in the cardiac
pathology of CO poisoning.63 Hypoxic stress from the formation of COHb is further
exacerbated by the increase in myocardial oxygen demand caused by the associated
changes in contractility and Q and can result in eventual cardiac failure. This COinduced cardiac hypoxia/ischemia injury pattern displays pathological and diagnostic
similarities to ischemic cardiac injury seen in the context of coronary artery
disease.52,61,64 Population studies and case reports have indicated that CO exposure
can create a pro-thrombic state, leading to an increased risk of arterial, venous, and
stent thrombosis. The mechanism behind this is not known.42
1.3.3 CO-Induced Myocardial Damage – Cellular Toxicity
The specific cytotoxic effects of CO on cardiac tissue are complicated and still
not fully understood. At the subcellular level, CO is both directly and indirectly toxic to
the mitochondria. When dissolved CO diffuses into the myocardium, it binds to the
heme complex of the intracellular O2 carrier myoglobin with an affinity 60-times greater
than that of O2. This displaces O2 and rapidly depletes the O2 supply to the
mitochondria, impairing oxidative phosphorylation.44
Direct mitochondrial toxicity of CO is once again, multifaceted and complex. CO
specifically binds and inhibits the terminal electron acceptor of the electron transport
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chain (ETC), cytochrome c oxidase (CcO), which causes uncoupling of the ETC and
impaired adenosine triphosphate (ATP) production.65,66 Cardiac muscle is then forced to
switch to anaerobic glycolysis to produce energy, resulting in lactic acidosis.59
Mitochondria continuously produce reactive oxygen species (ROS), commonly known
as “free radicals,” as a normal byproduct of oxidative phosphorylation. These ROS are
normally scavenged by the natural antioxidant glutathione. However, CO exposure
depletes glutathione levels in cardiac tissue, leading to unchecked ROS production, lipid
peroxidation, and tissue damage.59,67,68 At tissue concentrations greater than 88nM, CO
has also been shown to trigger apoptosis in endothelial cells via NO-mediated activation
of the pro-apoptotic enzyme caspase-1.69
Cardiac ion channels have recently been shown to be susceptible to modulation
by CO, however the effects and mechanisms are again poorly understood and no fully
comprehensive data on this phenomenon has yet been published.70 Acute CO exposure
is closely associated with the development of atrial and ventricular arrhythmias,
elongated QT intervals, and ischemic ST and T wave changes.44,59,61,70–73 The risk of
arrhythmia in CO poisoning increases if additional stress is placed on the heart and in
patients with existing cardiac pathology.71 The current leading theory behind the
development of arrhythmias in CO poisoning indicates that CO prolongs the late inward
Na+ flux of the Nav1.5 channel and the associated Ca2+ transient via NO-mediated
pathways, leading to action potential prolongation and early after-depolarization-like
arrhythmias.74,75
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Figure 3 – Pathophysiology of CO-Mediated Cardiotoxicity.
Adapted from: “Pathophysiology, clinics, diagnosis, and treatment of
heart involvement in carbon monoxide poisoning” by Lippi et al., 2012,
Clinical Biochemistry, 96:1278-1285. Copyright 2012, Elsevier.
Adapted with permission.
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1.3.3 The Respiratory System & Blood Chemistry in CO Poisoning
As expected with any hypoxic insult, CO poisoning is associated with a
compensatory increase in minute volume (MV) to attempt to compensate for the tissue
O2 deficit. This hyperventilation response to CO poisoning has been well documented in
human and animal subjects.76–79 But unlike hypoxic-hypoxia, such as from nitrogen
asphyxiation, pure CO poisoning is not associated with a significant decrease in the
arterial partial pressure of O2 (pO2) as the concentration of atmospheric O2 remains
relatively unchanged despite the presence of CO.76 In fact, CO poisoned victims tend to
demonstrate normal or increased arterial pO2 values and stable or decreased arterial
pCO2 values.76,77,80 However, accurate in vivo blood gas data on acute pure CO
exposure is limited and unreliable as many studies combined CO exposure with
decreased concentrations of O2 or attempted to model CO exposure using hypoxichypoxia alone.81,82 Pure CO poisoning differs from CO poisoning associated with smoke
inhalation, as other components of smoke will displace atmospheric O2 and create a
hypoxic environment.9
The MV increase seen in hypoxic-hypoxia is mediated by peripheral aortic pO2
chemoreceptors, whereas it is believed that the MV increase in CO poisoning is
mediated via central pH chemoreceptors that respond to the decrease in cerebrospinal
fluid (CSF) pH that accompanies cerebral lactic acidosis.76,77 Doblar and colleagues
also proposed that cerebral cortex hypoxia could lead to release of the normal inhibitory
influence of higher brain centers on respiratory drive.76
Acute pulmonary edema commonly accompanies severe CO poisoning and is
noted during autopsy in 66% of CO fatalities.48,83,84 While the exact mechanism(s)
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behind this remain elusive, rabbits exposed to 8000ppm CO balanced in air
demonstrated an increase in alveolar epithelium permeability resulting in
noncardiogenic pulmonary edema similar to that seen in humans.85 But given the
cardiotoxic effects of CO and left ventricular dysfunction seen severe CO poisoning, the
possibility of cardiac involvement in CO-induced edema formation has been reported
and cannot be ruled out without further research.86
The little reliable data on arterial blood gases in CO poisoning do not provide a
clear indication as to the presence and/or magnitude of arterial pH changes that may or
may not take place during exposure.76,76,80,87,88 Goats exposed to 10,000ppm CO in
40% O2 for 10 minutes demonstrated no significant changes in arterial pH, although
CSF pH did drop significantly.76,76 Sheep exposed to 10,000ppm CO in air for 35
minutes showed no changes in blood lactate levels or pH. CSF pH and brain tissue
lactate were not measured in this study, as the authors did not believe that appreciable
pH differences could be observed between blood and cerebral tissue comparments.89
Rats exposed to 10,000ppm CO in 40% O2 for 10 minutes showed decreases in arterial
pH from 7.47 to 7.24.87 Human studies have concluded that blood pH does not correlate
with %COHb, severity of exposure, patient acuity, or prognosis and has thus been
deemed of limited to no use in the clinical setting.88,90
Data on blood lactic acid levels in animal models of CO exposure are
inconclusive. No significant changes in lactate levels were appreciated in rat, dog, goat,
porcine and sheep models of CO poisoning. However, the concentration of CO used
and exposure time varied drastically between these studies.62,89,91–93 Unlike the
published animal models, lactic acid elevation has shown to be an effective indicator of
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prognosis following CO poisoning in human patients.49,94 Moon and colleagues reported
elevated lactate levels in 70% of CO poisoned patients that required inpatient
admission. There was no correlation between %COHb and prognosis in this study.49
1.4 Effects of CO on the Brain
1.4.1 Acute Pathophysiology
CO poisoning is associated with a broad spectrum of acute and chronic
neurological sequelae ranging from mild to severe. Mild CO exposure victims often
present with headaches, dizziness, nausea, and behavioral changes. Moderate and
severe CO exposures are associated with seizures, altered mental status, loss of
consciousness, cerebral edema and neuronal necrosis. The brain is the single most
oxygen-demanding organ in the body with approximately 50% of that oxygen being
utilized by the Na+/K+ ATP-ase, which maintains resting neuronal membrane
potential.95 Proper neuronal function depends on the presence of resting membrane
potentials, thus making cerebral tissue extremely sensitive to any hypoxic insult.
Irreparable neuronal damage results within 10 minutes of oxygen deprivation.96
Multiple lab groups hypothesized that COHb hypoxia causes quantifiable
decreases in animal whole body (VO2) or cerebral oxygen consumption (CMRO2) and
oxygen delivery (DO2), but these animal model data are conflicting. Smithline et al.
reported that whole body VO2 remained constant in a canine model of acute CO
exposure despite decreased DO2, however this study did not specifically examine
cerebral metabolism.62 Langston et al. reported just the opposite; their analysis of
cerebral metabolism in sheep showed that CO exposure caused a decrease in CMRO2
while DO2 was maintained.89 The literature review by Raub and Benignus concluded
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that cerebral DO2 remains stable and CMRO2 decreases in a statistically significantly
manner with %COHb >30%.98 However, a paper by Doblar et al. that was cited in this
review did demonstrate significant decreases in both DO2 and CMRO2 in goats when
%COHb rose above 30%, and no change in OER was noted.76
Analyses of the nicotinamide adenine dinucleotide (NADH) redox state with
reflectance fluorometry during CO exposure in rat brains sought to expose cerebral
hypoxia at the mitochondrial level. These studies failed to demonstrate significant
indicators of mitochondrial stress. Despite the absence of outward signs of cerebral
hypoxia, these rat studies curiously showed increased extracellular K+ concentrations
and spontaneous neuronal depolarizations, indicating dysfunction of the Na+/K+ ATPase. This was accompanied by decreased cerebral pH, which was hypothesized to be a
product of aerobic lactic acidosis.95,98 More recent investigations into the effect of CO on
mitochondria have provided convincing evidence that CcO inhibition may be the primary
acute effect of CO on cerebral metabolism.65,66,99–103
The stable DO2 seen in CO poisoning is due to a %COHb-proportionate
compensatory increase in cerebral blood flow (CBF) (with regional variations within the
brain) that has been well documented in small animals, large animals, and human
studies.89,104–107 In multiple human and animal studies on regional CBF immediately
following acute CO exposure, the cerebral cortex demonstrated the highest increases in
CBF while the basal ganglia, specifically the globus pallidus, demonstrated the lowest
relative increases in CBF.105–108 Perfusion of capillary beds increases uniformly
throughout the brain as well.87 The mechanism(s) behind the CBF increase have been
widely debated, with theories in published literature implicating tissue hypoxia, acidosis
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and hemoglobin-oxygen affinities.106,109–111 However, multiple recent studies have
shown that effects of CO on cerebrovascular modulation can be blocked to the
aforementioned NO-cGMP dependent pathways.54,112–114 Additionally, an increase in the
oxygen extraction rate (OER) is seen along with the increase in CBF, indicating that the
body is utilizing a rarely-used functional reserve of hemoglobin to sustain oxygen
delivery.62 Although current data on acute CO-mediated cerebral pathology implicates
mechanisms other than hypoxia, to the best of our knowledge, no published literature
on changes in brain tissue oxygen tension (PbtO2) during CO poisoning exists.
1.4.2 Delayed Pathophysiology
Despite the return of %COHb to normal physiological levels after exposure,
mitochondrial dysfunction can persist for days, leading to neuronal damage and death
via necrosis and apoptosis.99 This produces neurological deficits in up to in up to 33% of
patients that can last for months following exposure. Symptoms generally appear within
a week following exposure and can include, but are not limited to, dyskinesias,
Parkinsonian tremors, depression, learning impairments, difficulty focusing, and
amnesia.115,116 These prolonged neurological deficits are known as delayed neurological
sequelae (DNS) or prolonged neurological sequelae (PNS).115,117 DNS is closely
associated with lesions in the cerebral cortex, globus pallidus, and hippocampus, which
is not surprising given the functions of these regions of the brain in coordinating higher
learning, fine motor control and memory, respectively.97,118–121 These lesions are most
clearly seen in vivo using magnetic resonance imaging (MRI) techniques.121 Bilateral
globus palladi lesions with marked diffusion restriction on diffusion weighted (DW) MRI
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protocols are considered to be the “classic” radiological indicator of CO-induced
pathology in the days and weeks following CO poisoning.44,120,122,123
The mechanisms behind DNS are not fully understood, but are believed to be
immune-mediated secondary to unchecked ROS production and membrane lipid
peroxidation.113,115,117,118,124,125 As COHb dissociates following exposure, there is a
redistribution of dissolved CO into extravascular tissue driven by the CO partial
pressure gradient and high binding affinity of CO for intracellular targets like CcO.43
ROS are produced during uncoupling of the ETC and upregulation of NO synthesis by
neuronal NOS, resulting in the production of damaging peroxynitrite radicals.113 Unlike
cardiac tissue, brain tissue does not express myoglobin, a known CO buffer, and is
therefore more sensitive to the increase in ROS production, especially when coupled
with CO-mediated antioxidant depletion.124,126 A chain reaction of membrane lipid
peroxidation ensues, which disrupts normal membrane properties and triggers proapoptotic pathways.113,115,117
The variability seen between DNS prevalence and initial presentation has made
determination of DNS risk factors difficult. Although not 100% predictive, DNS has been
correlated with %COHb >25%, age >36 years, and exposure time >24 hours.127,128
1.5 Clinical Presentation, Diagnosis & Treatment of CO Poisoning
1.5.1 Clinical Presentation
The symptoms of CO poisoning are often vague. The most common complaints
of CO-poisoned patients are headache, dizziness, nausea, weakness, and vertigo.
Syncope, altered mental status, seizures, and decreased level of consciousness are not
uncommon with more severe exposures and are associated with poorer
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prognoses.44,48,97,129,130 Additional findings on presentation can include arrhythmias,
diarrhea, and abdominal pain.44,48 The often-described “cherry red” appearance of CO
victims taught to clinicians for decades is rare.131,132 This originated with the observation
that COHb exhibits a distinctly brighter red color than O2Hb by Hoppe in 1857.133 The
assumption was made that an increase in %COHb could be noted in the skin and
mucus membranes. Lethal levels of %COHb must be present before any changes in
epithelial color are noticed.134
Diagnosis of CO poisoning is difficult, if not impossible, to make based just on
symptoms alone and therefore requires accurate history taking sharp clinical acumen to
raise the index of suspicion and to avoid misdiagnosis. Acute CO poisoning can easily
go misdiagnosed as other acute low-acuity pathology like viral illnesses, acute anxiety,
or migraine headache. Chronic CO exposure can present similarly to psychiatric
illnesses like depression and psychosis.97,135,136 Misdiagnosis of CO poisoning can
endanger not only the patient, but clinicians and first responders as well if entry is made
into a hazardous environment, which was demonstrated when 12 fire-rescue personnel
were admitted for CO poisoning after treating a patient in a CO-filled house.136
1.5.2 Diagnostic Workup & Common Findings
Once suspicion of CO exposure has been raised, simple diagnostic confirmation
of CO exposure can be carried out via invasive or non-invasive %COHb analysis. Both
%COHb analysis techniques make use of the unique differences between the
spectrophotometric absorbance spectra of O2Hb and COHb to quantify %COHb, and
each has advantages and pitfalls.136–138 Invasive %COHb testing is considered the gold
standard of accuracy, but requires laboratory equipment and a blood sample. Non-
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invasive COHb-oximetry is portable, easy to use and interpret, and uses a finger probe
to assess %COHb. This technology has been reported to be less accurate than
laboratory testing, although still useful as a screening tool for occult poisoning.136 Many
fire departments and EMS agencies use this technology in conjunction with handheld
atmospheric CO detectors in both the emergency medical and fireground setting. These
allow for simple and rapid pre-hospital confirmation of CO poisoning which can aid in
determination of most appropriate patient destination in the field.137–139 Abnormal
%COHb levels are >3% for non-smokers and >10% for smokers, however it must again
be reiterated that %COHb holds no correlation to patient acuity.44,48,129,140
Patients with positive %COHb levels should undergo a full ED cardiac workup to
include ECG with close examination for ischemic changes and QT elongation, cardiac
biomarker evaluation, and chest x-ray.58,71,129,141 Elongated T-peak-T-end time has
recently been reported to be a reliable indicator of CO-induced cardiac injury as well.87
The utility of arterial blood gas analysis has been disputed, but lactate levels correlate
well to prognosis and should be evaluated.49,94 An echocardiogram is also
recommended for patients with signs of pulmonary edema.42,59 Patients presenting with
syncope, altered mental status, seizures, and decreased levels of consciousness
should undergo neurological imaging studies unless radiological studies would delay
transfer to a more appropriate treatment center.129,130 If available, magnetic resonance
imaging (MRI) is the preferred imaging modality for CO poisoning as it offers higher soft
tissue detail than computerized tomography (CT). Hypodensities in the basal ganglia
and cerebral edema are common acute findings in brain MRI and CT studies.120,121
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1.5.3 Current Treatment Modalities & Controversies
Despite over a century of medical research on CO poisoning, the treatment
remains unchanged. Oxygen therapy is currently the only accepted therapeutic agent
used for the treatment of CO poisoning. The goal of oxygen therapy is to decrease
%COHb using simple chemistry; providing an increased atmospheric pO2 to a COpoisoned patient shifts the equilibrium of COHb formation and favors dissociation of CO
from Hb.43,129,130 Although oxygen therapy is considered the gold standard of treatment,
it is based on the century-old theory that CO pathology comes from COHb formation
alone.
The most common method of O2 administration for CO victims is via the nonrebreather mask (NRB). At an O2 flow rate of 10-15L/min, the NRB is capable of
delivering 95-100% O2 at ambient atmospheric pressure to a patient and reducing
COHb t1/2 from 5 hours (breathing ambient air) to 60-90 minutes.9,129,142–144 In patients
unable to maintain their airway and/or respiratory drive, airway support and artificial
ventilation using high flow O2 must take the place of a NRB. This is otherwise known as
normobaric O2 (NBO). Equipment required to administer NBO is simple and cheap to
operate, readily portable, and easily accessible in hospitals, clinics, and EMS systems.
All emergency medical first responders are trained to administer NBO and the required
equipment to do so is required on any emergency response vehicle staffed by any
trained emergency medical technician (EMT) or higher.145 Administration of NBO prehospital reduces the time exposed patients have to wait to receive treatment, which is
considered to be equally, if not more important than treatment itself.43 American EMS
systems have a median BLS response time of less 10 minutes, which allows for
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extremely rapid O2 administration if CO exposure is suspected.146–148,148 Increased time
to treatment after CO exposure is associated with decreased efficacy of O2 therapy and
increased mortality and morbidity.43,131,149,150
The only significant advancement made in CO poisoning therapy was the
addition of hyperbaric O2 therapy (HBO) to existing O2 therapy protocols over 50 years
ago.151 HBO further exploits the mass-action effect of COHb equilibrium by application
of O2 at 2-3 times normal atmospheric pressure, further driving dissociation of CO from
Hb and can reduce COHb t1/2 to 15-30 minutes.48 While the optimal HBO dose is still yet
to be determined and protocols vary between facilities, most facilities employ a multitherapy protocol of 2.5-3.0atm for periods of 60-90 minutes in the days following
exposure.127,152–154 Criteria for HBO therapy generally include severe exposures, loss of
consciousness or syncope, neurological symptoms other than headache, age >36 years
and %COHb >25%. Pregnant patients are also HBO candidates due to the high affinity
of fetal Hb for CO discussed previously.48,127,154 However, no standardized criteria for
HBO therapy currently exist, and thus vary widely between facilities equipped to provide
it.155
HBO therapy is considered the modern gold standard for severe CO exposure,
but it is not without limitations. Few hospitals are equipped with critical care hyperbaric
chambers and the cost of operation is exorbitant. Patients often require transfer to a
tertiary facility and the logistics of interfacility transport and hyperbaric chamber
preparation can further increase time to HBO therapy, which is associated with a
decrease in HBO efficacy and an increase in morbidity and mortality.131,149,150
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Interfacility critical care transport is also expensive, with helicopter EMS transport
(HEMS) costs of approximately $20,000 per flight.156,157
There is no question that both modalities hasten the dissociation of CO from Hb
through basic biochemical mechanisms; this phenomenon has been well documented
since the early 20th century.127,154,158,159 But despite decades of use, the efficacy of both
O2 therapy modalities remains widely debated in the literature. Recent studies have
found that the data on %COHb reduction with NBO are unreliable and that NBO does
not offer any protection from DNS compared to breathing ambient air.159–161 Efficacy of
HBO compared to NBO also remains to be definitively elucidated. Due to a 3% mortality
rate of CO-exposed patients presenting to hospitals and no published data
demonstrating that HBO decreases mortality, the goal of HBO therapy is to prevent
DNS, not to prolong short-term survival.127 Published studies on the efficacy of HBO are
fraught with methodological limitations that make drawing conclusions difficult, but some
indicate that HBO provided without delay is effective at ameliorating cellular damage
and DNS in human and animal models.66,115,127,128,131,153,161,162,162,163 Other studies and
retrospective reviews of existing data were unable to demonstrate any benefit from HBO
therapy.43,160,164,165
Additional arguments have been made that O2 therapy can actually exacerbate
CO-induced oxidative stress. Oxygen therapy, particularly HBO, induces ROS
production in proportion to the pO2 in the chamber and time of treatment, leading to
DNA damage, membrane lipid peroxidation, and activation of pro-apoptotic
pathways.166–170 CO-mediated ROS formation, antioxidant depletion, and subsequent
cellular damage have been implicated as major pathophysiological mechanisms in CO
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poisoning.59,67,68,113,117,118,124,125 Although it remains to be definitively studied, it is
therefore likely that the oxidative stresses from O2 therapy and CO poisoning are
additive, which could exacerbate pathology.125 Oxygen is also a potent respiratory
stimulant. Hyperoxia-induced hyperventilation results in hypocarbia, triggering
vasoconstriction in CO2-sensitive vascular beds in the heart and brain, reducing blood
flow.43 This phenomenon occurs even in the presence of CO and can result in
decreased DO2 to these tissues despite the increase in pO2.43,171
Exploration into therapies other than O2 has, much like O2 therapy, hinged upon
the hypoxic theory of CO poisoning. Attempts to increase oxygen delivery have included
the use of artificial oxygen carriers (perfluorocarbons and hyper-oxygenated saline) and
early attempts using blood transfusions, but these have not been adopted into clinical
practice.172–175 Recent studies have found success in utilizing extracorporeal membrane
oxygenation (ECMO) to reduce COHb and reverse acidosis in severe cases of CO
poisoning, but no data exists on the effects of ECMO therapy on long-term
outcomes.176,177 Before the rise of HBO as the standard of care in the 1960’s, an inhaled
mixture of oxygen and CO2 (carbogen) was employed to decrease %COHb by
triggering hyperoxic hyperventilation while maintaining a normocarbic state. Fisher and
colleagues are attempting to bring this treatment modality back into favor.43
Few attempts have been made to target the effects of CO not mediated by COHb
formation. Qingsong and colleagues successfully demonstrated amelioration of DNS
pathology following CO exposure using the free radical scavenger edavarone, but no
further data is available on this.178
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The current lack of therapy options for CO-poisoned patients presents a clear
and present need for a replacement or adjuvant therapeutic options. The ideal treatment
would be portable, robust, safe, and easily deployed in the field by paramedics. It would
be efficacious at mediating the well known harmful effects of COHb formation as well as
the less understood but ever present cytotoxic mechanisms.
1.6 A Potential Antidote
1.6.1 Hydroxocobalamin
Hydroxocobalamin (OHCbl) is a member of the vitamin B12 family, a group of
four compounds (hydroxocobalamin, cyanocobalamin (CNCbl), methylcobalamin, and
andenosylcobalamin) that differ only by a single upper axial side chain. These
compounds exhibit a marked structural similarity to the heme moiety of Hb, differing
only by one carbon atom and a central cobalt atom instead of iron.179 Physiologically,
cobalamins serve as cofactors for the methylmalonyl-CoA mutase catalyzed
isomerization of methylmalonic acid to succinate and the methionine synthasecatalyzed synthesis of methionine from homocysteine and 5-methyltetrahydrofolate.180
For the past 40 years it has been used in high doses (5-15g) as a safe and
effective antidote for cyanide exposure, acting similarly to a chelating agent by binding
cyanide to become CNCbl.181,182 Hydroxocobalamin is also capable of scavenging free
NO and inhibiting NOS resulting in vasoconstriction and an increase in blood
pressure.183–185 This effect has been shown to mitigate endotoxin-induced hypotension
in rats and has most recently been employed to counteract vasoplegic syndrome in a
human case study following cardiac surgery by Roderique and colleagues.186,187 The
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vitamin B12 family also demonstrates remarkable anti-inflammatory and antioxidant
properties, capable of scavenging free radicals and downregulating the expression of
pro-inflammatory cytokines and transcription factors.188,189

1.6.2 Reduced Hydroxocobalamin & CO
In the late 1960’s, the lab group of Schrauzer and co-workers postulated that
OHCbl would be capable of reacting with CO, given the affinity of CO for hemecontaining proteins and the structural similarities between heme moieties and OHCbl.
They successfully demonstrated that OHCbl is capable of reacting with free CO and
forming CO2, but only when OHCbl was in its reduced state, that is, with the central
cobalt atom reduced from the Co3+ state to Co2+. Reduced OHCbl will herein be referred
to interchangeably as B12r, with OHCbl referring to the unreduced form of the
compound. The same reaction was attempted with carboxyhemoglobin, but was unable
to produce decarbonylation from Hb-bound CO.190 No further investigation into this
phenomenon was published until 2013.
Based on the work performed by Schrauzer in the 1960’s, a second attempt at
reacting B12r with carboxyhemoglobin was undertaken by Roderique and colleagues at
Virginia Commonwealth University to test the viability of B12r as a potential therapy for
CO exposure. B12r was produced by combining OHCbl with ascorbic acid (vitamin C,
AA) as a reducing agent in an nitrogenous environment.191 Ascorbic acid was chosen
because of its powerful action as a reducing agent and safety when administered in
large doses.192 Confirmation of the presence of B12r was performed by Raman
resonance spectroscopy (RRS). Using a closed-loop circulatory system containing
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whole human blood and a CO2 analyzer, they were able to demonstrate increased
release of CO2 from CO-poisoned blood after B12r injection compared to unpoisoned
blood. It was hypothesized that B12r was reacting with COHb, catalyzing the
dissociation of CO from Hb and oxidizing CO to CO2 via an unknown mechanism191
Further in vitro work by Somera and co-workers probed these findings using additional
Raman analysis techniques. The data from these experiments indicate a significant
%COHb decrease in CO-poisoned human whole blood following B12r administration.193
The in vitro data from the work by Roderique and Somera indicate that B12r could
potentially function as a therapeutic agent for CO poisoning by interacting with and
driving dissociation of COHb.
1.7 Hypotheses & Specific Aims
The data obtained from work by Roderique and Somera et al. suggest that B12r
is capable of reacting with CO in blood and decreasing %COHb in vitro.191,193
Hydroxocobalamin also a potent NO scavenger and NOS inhibitor, causing an increase
in blood pressure when administered.183–185,187 Additionally, OHCbl is a powerful
antioxidant and anti-inflammatory capable of neutralizing ROS and downregulating proinflammatory mediators.188,189 This trifecta of pharmacological mechanisms implicates
B12r as a potential therapy for CO poisoning. This work was a direct outgrowth of the
work by Roderique and Somera..
Additionally, there are currently no published data on changes in brain tissue
oxygen tension (PbtO2) during and after CO exposure despite ongoing literature debate
about cerebral perfusion and metabolic changes in CO poisoning. Using a
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multiparametric monitoring approach in a non-survival surgical model, we aimed to
characterize the physiological effects associated with acute CO exposure in a rat model
by examining changes in brain tissue oxygen tension, mean arterial blood pressure
(MAP), respiratory rate, and arterial blood gas chemistry. We also aimed to evaluate the
efficacy of B12r as a therapeutic agent for CO poisoning by observing for rescue from
CO pathology in comparison to control rats administered a normal saline vehicle.
Specifically, we hypothesized that:
1. CO poisoning will decrease PbtO2 significantly in rats exposed to CO as
measured by a Licox® Clark-type polarographic electrode placed into the
cerebral cortex.
2. Administration of B12r could rescue PbtO2 of CO-exposed rats within 20
minutes of administration. Additionally, B12r administration would cause a MAP
increase within 20 minutes and/or demonstrate blood chemistry improvement
within 60 minutes in comparison to controls.
3. B12r would produce the same increase in CO2 off-gassing in vivo as seen in
prior in vitro work, demonstrated by an increase in observed respiratory rate
and/or increase in arterial pCO2 within 20 minutes in comparison to controls.
1.8 Basic Approach
1.8.1 Non-Survival Surgery
Physiological parameters of anesthetized rats were recorded during a nonsurvival procedure. Parameters monitored included PbtO2 via microelectrode, arterial
blood pressure via femoral artery catheter, respiration rate, and arterial blood gas (ABG)
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chemistry. Rats were anesthetized using inhaled isoflurane and were not intubated in
order to preserve natural compensatory changes in respiratory drive. Following surgical
placement of monitoring equipment and stabilization, rats were randomly assigned to an
exposure group to receive either 3000ppm CO balanced in medical air or medical air
(sham exposure), both of which were mixed with 2% isoflurane. After exposure, all rats
were switched back to breathing medical air and administered a randomly assigned
intraperitoneal (IP) injection of either 100mg/kg B12r (50mg OHCbl+50mgAA/mL in
deoxygenated saline) or equivalent volume of normal saline (vehicle) and monitored for
60 minutes. Respiratory rate and PbtO2 were recorded every 5 minutes during exposure
and after treatment. Serial ABG samples were taken prior to exposure and at three time
points after exposure. Rats were humanely euthanized after 60 minutes of monitoring. A
visual representation of the procedure timeline is below in Figure 4.
B12r or
Vehicle Rx
ABG

Monitor Placement &
Stabilization
(Approx. 90 min)

ABG

CO or Sham
Exposure

ABG

ABG

Post-Treatment Monitoring
Licox®, RR, MAP Monitored

0 min

+30 min

+50 min

Figure 4 – Visual Representation of Surgical Procedure Timeline.

+90 min
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1.8.2 Brain Tissue Oxygen Tension Monitoring
We measured PbtO2 via a Licox® (Integra Neuroscience™) CC1.R Clark-type
polarographic oxygen-sensitive electrode and associated AC31 monitoring system
placed into the cerebral cortex of anesthetized rats at -1mm anteroposterior, -3mm
mediolateral with respect to Bregma using stereotaxic technique. This region of the
brain was chosen for evaluation due to the prevalence of literature on rat cerebral cortex
pathology in CO exposure.95,98,119,194 Licox® technology has been used extensively in
clinical treatment and research of stroke and traumatic brain injury.195–198 The
microcatheter contains a 1mm oxygen-sensitive electrode that consists of gold and
silver electrodes within an oxygen-permeable membrane and measures the partial
pressure of dissolved oxygen in the extracellular space. Dissolved oxygen diffuses
across the membrane and is reduced by the electrode in a temperature-dependent
reaction, creating a current proportional to the concentration of oxygen.199
This device allows for real-time analysis of PbtO2, which is believed to represent
the balanced between O2 delivery and consumption, reflecting the availability of O2 for
metabolic processes. Normal PbtO2 range is 20-35mmHg, although this can vary
depending on the study and species evaluated. Reported mean normal PbtO2 values
were 29.4mmHg in a murine study, 28mmHg in dogs, 42mmHg in cats, and 33-36 in
humans.200 The critical PbtO2 for normal human brain tissue is between 15-20mmHg,
below which infarction can occur.201 Values below 15mmHg are considered hypoxic and
are associated with poor outcomes.199
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A

C

B

Figure 5 – Licox® Brain Tissue Oxygen Tension Electrode. (A) Schematic
representation of Licox® electrode oxygen-sensitive tip. 1, Polyethylene tube with
oxygen-permeable membrane; 2, gold cathode; 3, silver polarographic anode; 4,
electrolyte chamber; 5, brain tissue. (B) Photograph of the tip of the Licox®
electrode used. Black circle is placed around the oxygen-sensitive portion. (C)
Photograph of the entire electrode assembly.
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1.9 Summary of Findings
There were no deaths during the procedures. There were no significant
differences between baseline parameters of groups. All rats exposed to CO
demonstrated marked decreases in PbtO2 and MAP during exposure. Mean PbtO2
values decreased from 31.3±1.2 to 18.3±1.0 mmHg and 31.2±0.7 to 18.3±1.3 mmHg at
end of CO exposure in B12r-treated (n=10) and vehicle-treated rats (n=10), respectively
(p<.0001). Baseline MAP recordings were 88.23±3.24 in CO-B12r and 89.32±3.54 in
CO-Vehicle groups. Post-exposure, CO-B12r and CO-vehicle MAP recordings were
46.23±1.81 and 45.35±2.01, respectively (p<.0001, compared to sham-exposed
groups). Lactic acid levels were significantly increased after exposure in CO-exposed
groups with mean lactate levels >3.0mM. This was associated with significant
hypocarbia and decreases in HCO3- (p<.05). Exposure to CO caused a decrease in
respiration rates with observed tidal volume increase and Kussmaul-like respiration
pattern in CO-exposed groups. Rats not exposed to CO did not demonstrate
appreciable changes in PbtO2 or MAP during sham exposure. Respiration rates
remained constant in Sham-B12r and Sham-vehicle groups.
PbtO2 values remained <25mmHg for 40 minutes after exposure and remained
below baseline levels in the CO-Vehicle group. The CO-B12r group demonstrated rapid
recovery of PbtO2 to >25mmHg and MAP to >75mmHg within 15 minutes of treatment.
CO-Vehicle group MAP was significantly lower than sham-exposed groups during the
entirety of post-exposure monitoring (p<.001). A significant transient MAP increase was
seen in the Sham-B12r group 5 minutes after treatment that persisted for 15 minutes
(p<.05). No significant blood chemistry differences were noted between CO-B12r and
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CO-vehicle rats after treatment. Lactic acid levels in CO-exposed groups decreased
throughout monitoring without significant difference between the groups. Respiratory
rate remained significantly lower in the CO-B12r compared to the CO-Vehicle group for
25 minutes after treatment. Sham-B12r and sham-vehicle groups demonstrated normal
arterial blood gas composition at all time points and did not exhibit lactic acidosis,
indicating adequate surgical technique and anesthetic management.
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MATERIALS & METHODS
2.1 Materials
Ascorbic acid and hydroxocobalamin were obtained from Sigma-Aldrich and
were of analytical grade. All gases were obtained from Airgas™ and contents certified
by the manufacturer. Gases used were medical air, USP and 2500ppm CO balanced
with medical air. Licox® components were obtained from Integra Neuroscience™; a
CC1.R probe (0.5mm diameter, 1.0mm sensitive tip) was used to measure PbtO2 in
conjunction with the AC31 PbtO2 monitor and calibrated for temperature using the C8.B
temperature probe. The stereotaxic frame used was a Stoelting™ model 51500 singlearm dual rat/mouse frame. Blood pressure was monitored using the MP150® hardware
system in conjunction with AcqKnowledge 4.0® software. Blood gas analysis was
performed using a Radiometer™ ABL 800 Flex clinical blood gas analyzer.
Surgeries were performed inside of a fume hood in order to minimize any escape
of carbon monoxide. Inside of the fume hood was a full compliment of surgical lights,
instruments, and an electric homeothermic heating pad with rectal probe. The surgical
suite setup for arterial line placement is depicted in Figure 6, setup for Licox®
monitoring is depicted in Figure 7.
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Figure 6 – Surgical Equipment for Arterial Line Placement. (1) Dissecting microscope;
(2) lights, (3) homeothermic warming unit (warming pad underneath drape, rectal probe in
center of drape); (4) surgical instruments, catheter material, suture material; (5) pressure
transducer; (6) BioPac™ MP150®; (7) digital clock. Not pictured: anesthesia equipment,
gas tanks.
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Figure 7 – Surgical Equipment for Licox® Electrode Placement & Monitoring. (1)
Dissecting microscope, moved out of suite; (2) lights; (3) homeothermic heating equipment;
(4) surgical instruments; (5) pressure transducer; (6) BioPac™ MP150®; (7) digital clock; (8)
loupes; (9) stereotaxic frame and anesthetic nose cone; (10) stereotaxic manipulator arm;
(11) Licox® oxygen and temperature probes taped to manipulator arm; (12) Licox® cables;
(13) digital timer. Not pictured: Licox® AC31 monitor, Dremel® tool, anesthesia machine.
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2.2 Production of Reduced Hydroxocobalamin
Powdered hydroxocobalamin and ascorbic acid (AA) were obtained from SigmaAldrich. Hydroxocobalamin was stored in a dark brown glass bottle at 4°C in a dark
refrigerator until needed. Ascorbic acid (AA) was stored in a sealed polypropylene
container at ambient temperature until needed. Deoxygenated saline was produced by
bubbling nitrogen through a 0.9% saline solution in an Erlenmeyer flask under a vacuum
for 90 minutes before transfer into the nitrogenous environment within an airtight glove
box. Antidote was produced using 50mg OHCbl and 50mg AA per mL of deoxygenated
saline. This 1:1 mass ratio ensured adequate reduction of the OHCbl to B12r as noted
by Raman analysis with the assistance of Capt. Leo Somera.193
Each dose of antidote was created individually. Using an analytical balance,
50mg of OHCbl and AA was measured out into separate 5mL syringes with plungers
removed. The two syringes were then placed into the airlock of our glove box and the
airlock was flushed with gaseous nitrogen for a minimum of seven minutes to remove
any ambient air. The syringes were then moved into the glove box, which contained a
100% nitrogen environment to prevent oxidation of the antidote from atmospheric O2.
Using a third syringe, a 1mL aliquot of deoxygenated saline was injected into the
syringe containing the AA. This syringe was then connected to a three-way stopcock
along with the syringe containing the OHCbl. The AA/saline solution was flushed back
and forth between the two syringes for a minimum of 30 seconds to agitate the reagents
and allow proper mixing. The mixture was then transferred into one syringe and capped
with a needle. Antidote preparations were left in the nitrogenous environment until
needed and were warmed on the heating pad prior to administration.
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2.3 Animals & Ethics Statement
All procedures followed the guidelines established in the Guide for the Care and
Use of Laboratory Animals (U.S. Department of Health and Human Services) and were
approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University (Protocol Number AD10000569). The surgical procedure
was observed and approved by VCU Department of Animal research veterinary staff.
Male Sprague-Dawley Rats (SD rats) were used for surgical procedures. Rats were
obtained from Harlan Laboratories, Inc, and weighed 315-370g on the day of the
procedure. All rats were housed two per cage in a 12-hour on/off light cycle vivarium
with ad libitum access to food and water. VCU Department of Animal Resources staff
carried out all cage maintenance and provided enrichments. Rats were acclimated to
the lab and vivarium with weights monitored daily for a minimum 7 days prior to surgical
procedures. During acclimation, rats were habituated to handling by experimenters.
2.4 Non-Survival Surgical Procedure
2.4.1 Experimental Group Assignment & Procedural Preparation
Rats were divided into 4 groups according to assigned exposure (CO or sham)
and treatment (B12r or normal saline “vehicle”) received. Experimental groups are
outlined in Table 1. Assignment of rats to experimental groups was randomized.
Table 1 – Experimental Exposure-Treatment Groups and Sample Sizes
Exposure-‐
Treatment	
  
Sample	
  Size	
  (n)	
  
CO-‐B12r	
  
10	
  
CO-‐Vehicle	
  
10	
  
Sham-‐B12r	
  
5	
  
Sham-‐Vehicle	
  
5	
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Prior to the start of surgeries, all instruments and work areas were cleaned. All
equipment was prepped and checked for proper function. The blood pressure
transducer was calibrated at 0mmHg using ambient air pressure and 120mmHg using a
mercury sphygmomanometer. Each rat was weighed prior to anesthesia induction. This
surgery was a non-survival procedure, so aseptic technique was used, as opposed to
sterile technique.
Anesthesia induction took place in an induction chamber mounted to the
anesthesia machine. Rats were induced with 4% isoflurane balanced in medical air for 3
minutes. Following induction, the rat was then removed from the chamber and hair was
clipped over the left inguinal area and superior aspect of the head. If the animal moved
during clipping, it was placed back into induction chamber at 4% isoflurane until
cessation of movement. The rat was then placed supine on the surgical table and the
nose inserted into a nose cone delivering anesthetic gas. Isoflurane was reduced to 2%
after induction. A digital homeothermic heating pad placed dorsally on the rat and rectal
temperature probe were used to maintain a core temperature of 36.6°C. Anesthesia
checks were performed every 15 minutes by pinching the toes and observing for a painwithdrawal response.

2.4.2 Femoral Artery Cannulation
The arterial catheter was prepared prior to the start of surgery and consisted of a
3-4” length of PE-50 tubing with a one-way pin port connected to one end. The volume
of the catheter was determined using a 1mL syringe; catheter volume was between 4070μL. Each catheter was flushed with a 4u/mL heparinized saline solution.
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Using forceps and blunt dissection scissors, a 2cm incision was made into the
left inguinal crease. Skin and subcutaneous tissue were then retracted. The entire
surgical site was irrigated with 0.25% bupivacaine warmed on the homeothermic
heating pad and allowed to sit on tissue for minimum 1 minute before removal with
gauze. The femoral artery was located and dissected away from the femoral vein and
sciatic nerve using microsurgical forceps under a dissecting microscope. The artery was
ligated proximal to the bifurcation of the epigastric artery using a surgeon’s knot in 4-0
silk. A hemostat was clipped to the ligature tail and gently retracted to pull distal traction.
A second ligature of using 4-0 silk was passed underneath the artery proximal to the
initial ligature. A single overhand knot was placed into the thread, which was then
clipped to hemostats and retracted towards the midline to close off the arterial lumen.
Using microsurgical scissors, an incision was cut across 1/3 of the arterial wall between
the ligatures. The opening was retracted using microsurgical forceps and a short length
of PE-50 tubing was threaded into the arterial lumen. Proximal ligature traction was
reduced, and the catheter advanced approximately 1-2cm. The catheter was then
aspirated for blood return and flushed with 4u/mL heparinized saline to prevent
coagulation. The proximal ligature was then tightened and secured with a surgeon’s
knot. The incision was closed with staples or continuous suture using 2-0 nylon. The rat
was then moved back into induction chamber with 2% isoflurane maintained in order to
prepare the surgical area for Licox probe insertion. Isoflurane concentration was
adjusted in small percentages in order maintain non-responsiveness to foot pinches.
Blood loss during arterial cannulation was estimated to be less than 100μL for each rat
by using 1 or less cotton-tipped applicators for bleeding control. This technique was
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adapted from Jesperson, et al. with additional technical guidance provided by VCURES
professors Dr. Jiepei Zhu and Dr. Penny Reynolds.202
2.4.3 Licox® Placement
The dissection microscope was swung out of the surgical suite and the heating
pad removed. The stereotaxic frame was placed centrally into the surgical suite and the
heating pad placed on top of the frame platform then covered with a clean drape. A
stereotaxic nose cone was used to deliver anesthetic gas. The rat was placed onto the
stereotaxic frame and the head secured in a level position via ear bars and nose cone.
Once secured, the pin port of the arterial cannula was connected to the pressure
transducer and arterial pressure monitoring was initiated. Arterial blood pressure was
monitored continuously for the remainder of the procedure.
A midline incision was made down the length of the skull using a #11 scalpel and
the incision was retracted using microsurgical retractors. The periosteum was peeled
away from the skull using forceps. A 19-guage needle taped to the arm of the
stereotaxic frame served as a navigation guide. Under 10x loupe magnification, the
Bregma point was located on the skull by locating the intersection of the coronal and
sagittal sutures. The coordinates of the Bregma point were recorded. The region of
interest (ROI) coordinates were then calculated by moving the needle 1mm posterior
and 3mm lateral (written as -1mm AP, -3mm ML) with respect to Bregma to allow for
access to the primary somatosensory cortex. The right side of the skull was used on
each rat to maintain consistency. This location was marked with a felt-tip pen and the
stereotaxic manipulator arm was removed. This location would be used for insertion of
the Licox® oxygen-sensing electrode. A second location was marked contralaterally at
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the approximate same location to serve as the insertion point of the temperature probe;
placement of this probe did not require specific stereo taxic coordinates.
Access to the cranial vault was achieved using a Dremel™ tool with a 2mm burr
drill bit. In order to prevent major damage to brain tissue caused by the Dremel™ drill, a
technique was devised to safely drill burr holes. Using two hands, the drill was slowly
advanced through the roof of the cranium until a thin, pliable film of bone remained. A
small hook was created on the end of a 19-guage needle by applying repetitive blunt
force to the tip of the needle against the lab bench in order bend the tip of the needle
towards the bevel. The bent tip of the needle was then used to gently puncture the edge
of the thin bony film and gently lift it away from the underlying brain tissue. Forceps
were then used to extract the disk. This process was repeated for both marked sites.
The dura mater was gently pierced and incised using the same bent tip of the needle
used to remove the film from the craniotomy site. Bilateral craniotomy burr holes are
pictured in Figure 8.
The Licox® CC1.R electrode hub was then taped to the top of the manipulator
arm and the electrode tip taped to the end of the arm with an approximately 1cm
overhang of the probe tip. The hub of the temperature probe was then taped to the shaft
of the manipulator arm, as shown in Figure 9A. The manipulator arm was positioned
with the CC1.R probe tip over the insertion site and the tip was lowered to the surface of
the brain tissue. Using loupe magnification and fine adjustment knobs of the
manipulator arm, the probe was then lowered into the brain parenchyma to a depth of
2.3mm. This depth ensured that the 1mm oxygen-sensitive portion of the electrode
would be positioned within the cortex. Catheter placement is depicted in Figure 9B. The

43
temperature probe was then inserted into the respective insertion site and both probes
were connected to the Licox® AC31 monitor, which was then powered on. The probes
were then allowed to equilibrate and stabilize for 30 minutes. Anesthetic gas was
maintained at 2% for the remainder of the procedure to ensure consistency. All rats
were stable at this concentration of isoflurane.

1
3
2

Figure 8 – Bilateral Craniotomy Holes. (1) CC1.R oxygen probe site (1mmAP, -3mmML); (2) Bregma point; (3) CB.8 temperature probe site.
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Figure 9: Licox® PbtO2 Electrode Preparation & Placement (A)
Licox® electrodes taped to stereotaxic manipulator arm. PB) Electrodes
after placement into brain parenchyma. (1) Licox® CC1.R probe; (2)
Licox® C8.B temperature probe.
2.4.4 Insult, Treatment, & Post-Treatment Monitoring
Following the 30-minute stabilization period, a 100μL arterial blood sample was
aspirated from the arterial cannula and analyzed using the ABL 800 Flex® blood gas
analyzer. The following parameters were analyzed during blood gas analysis: pH, pO2,
pCO2, HCO3-, ctHb, %COHB, and lactic acid concentration. The arterial line was then
flushed with a volume of heparinized saline equal to the catheter volume in order to
remove blood from the catheter lumen. Exposure procedure was then initiated. This
time point was flagged in the AcqKnowledge software for later reference and is
considered Time 0, as per Figure 4. Rats were exposed for 30 minutes to either
2500ppm CO balanced in medical air (insult) or medical air (sham exposure). PbtO2
was recorded every 5 minutes beginning at Time 0. Respiration rate was also recorded
every 5 minutes concurrently with PbtO2 recordings by observing chest rise for 30
seconds and multiplying the observed rate by a factor of 2. Isoflurane was continuously
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administered at 2% with the assigned exposure gas. At the end of exposure protocol,
Time 30, another 100μL arterial blood sample was obtained and analyzed. This time
point was marked in the AcqKnowlege software. All rats were immediately switched
back to breathing medical air with 2% isoflurane and each rat was administered
administered the assigned IP injection of B12r according to a weight-based dosing
scheme given in or an equivalent volume of isotonic normal saline (Table 2).
Intraperitoneal administration was chosen to maintain consistency with methods used in
previous studies conducted in our laboratory on B12r as a potential therapy for CO
poisoning.

Table 2 – B12r Dosing Protocol
Dose: (100mg OHCbl + 100mg
AA)/ kg
Weight
(g)

Dose
OHCbl +
AA (mg)

300 30 + 30
32.5 +
325
32.5
350 35 + 35
37.5 +
375
37.5
40.0 +
40.0
42.5 +
425
42.5
400

Dose
Volume
(mL)
0.6
0.65
0.7
0.75
0.8
0.85

A 1:1 mass ratio of 50mg/mL OHCbl and AA was used and administered at
100mg/kg intraperitoneally. Rats assigned to vehicle treatment received an
equivalent intraperitoneal dose of normal saline.
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PbtO2 readings were recorded every 5 minutes for another 60 minutes.
Additional arterial blood samples were obtained and analyzed at 20 and 60 minutes
(Time 50 and Time 90, respectively) after treatment administration. The 20 minute postadministration time was chosen because we noted that rats receiving B12r were
excreting purple urine 15-20 minutes following intraperitoneal injection, indicating that
the treatment was not only in the vasculature but also being actively cleared by the
animal’s renal system. Monitoring was terminated 60 minutes after antidote
administration (Time 90) and each animal was humanely euthanized via IP injection of a
high-dose pentobarbital and phenytoin solution (Euthasol®, Virbac Animal Health™).
Upon completion of the procedure, mean arterial pressure data were obtained
using the hemodynamic analysis algorithm within the AcqKnowledge software. A 30second period of time was selected at 5 minute intervals to correspond with PbtO2
measurements and the mean arterial pressure was recorded.
2.5 Statistical Analysis
PbtO2 and MAP data were analyzed using the SAS™ software Type 3 Tests of
Fixed Effects analysis algorithm and paired Student’s t-tests with corresponding p<.05
considered significant. Arterial blood gas parameters and respiratory rate data were
analyzed using StatPlus Pro™ two-way ANOVA. Fisher Least Square Difference tests
and paired Student’s t-tests were used for inter-group comparisons with corresponding
p <0.05 considered significant.
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RESULTS
3.1 Brain Tissue Oxygen Tension Results
Mean PbtO2 values and standard deviations were calculated for all
measurements (Table 3) and plotted against respective time points (Figure 10A). Mean
percent change and standard deviation from PbtO2 baseline was calculated and plotted
as well (Figure 10B). The individual PBtO2 trajectories with calculated means for
subjects in each test group are presented in Figures 11A-D.
Statistical data were performed using SAS™ Type 3 Test of Fixed Effect
ANOVA, which was felt to be a more appropriate algorithm than standard two-way
ANOVA in order to account for individual subject baseline differences. Inter-group
significance calculations at relevant time points were carried out using paired Student’s
t-tests in order to avoid the inherent increased risk of falsely significant differences
associated with use of population-derived means in variance analysis. Summary
statistical data and relevant inter-group comparisons are given in Table 4. Reported FValues indicate significant effect on PbtO2 over time and between groups (F=248.94,
p<.0001; F=56.14, p<.0001).
No statistical difference was noted between all groups prior to start of the
exposure protocol (Table 3). All rats exposed to CO exhibited marked decreases in
PbtO2; mean PbtO2 decreased from 31.3±1.2 mmHg to 18.3±1.0 mmHg in CO-B12r rats
and from 31.2±0.7 mmHg to 18.3±1.3 mmHg in CO-Vehicle rats (p<.0001 in comparison
to baseline and sham-exposed groups). There were no statistical significances between
the PbtO2 values of the two CO-exposed groups after or during the 30-minute exposure
(p>0.5, p=1.0 at end of exposure). Sham-B12r and Sham-Vehicle rats did show a small
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PbtO2 increase during exposure from 30.7±0.6 to 31.2±1.0 and 30.6±0.6 to 31.7±9,
respectively (p<.05). There was no statistical difference between the PbtO2 of the two
sham-exposed groups (p>0.2).
Neither B12r nor Vehicle treatments had a significant effect on PbtO2 in shamexposed rats as compared between and within the two sham groups and (p>0.1).
Poisoned rats treated with B12r demonstrated a rapid PbtO2 increase with recovery to
above the published murine mean PbtO2 of 29.4mmHg within 55 minutes of
administration (29.8±1.9 mmHg, p<.0001). There was no statistical significance
between the CO-B12r group and Sham groups 35 minutes after treatment (p<.05). The
recovery seen in the CO-Vehicle group was significantly slower in comparison to the
CO-B12r group; PbtO2 did not reach >25mmHg until 45 minutes post-treatment and did
not return to baseline (p<.0001 compared to sham groups at all time points after
treatment). Differences in PbtO2 between CO-B12r and CO-Vehicle rats were
statistically significant for all time points after administration (p<.0001).
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Table 3 - Mean PbtO2 Values and Standard Deviations of the
Mean
Time

CO-B12r

0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90

31.3±1.2
26.9±1.4
23.3±1.5
21.4±1.2
19.8±1.0
18.9±1.0
b
18.2±1.0
d
20.9±2.0
e
23.5±1.7
25.8±2.0
28.2±1.8
29.4±1.9
30.3±1.9
30.5±1.1
30.9±0.7
31.1±1.3
31.1±1.0
31.4±1.0
e,f
31.8±0.9

a

COVehicle
a
31.2±0.7
25.9±1.8
22.8±1.4
21.4±1.7
20.1±1.6
18.7±1.0
b
18.2±1.3
19.2±1.3
20.1±1.7
20.9±1.6
22.0±1.5
23.0±0.6
23.6±0.8
24.4±0.6
24.8±0.7
25.8±1.4
26.1±1.6
26.8±1.8
g
26.9±1.9

ShamB12r
a
30.7±0.6
30.5±0.4
30.6±0.4
30.9±0.7
30.9±0.5
30.8±0.7
c
31.2±1.0
31.2±1.1
31.3±1.0
31.8±1.0
31.7±0.7
32.0±0.7
31.9±0.9
31.5±0.9
31.6±0.7
31.6±1.1
31.4±1.3
31.2±0.9
31.4±0.9

ShamVehicle
a
30.6±0.6
30.9±0.6
30.9±0.5
31.0±0.6
31.2±0.4
31.5±1.1
c
31.7±0.9
31.8±1.0
31.7±1.2
31.5±1.2
31.4±1.1
31.5±1.0
31.5±1.0
31.4±0.9
31.5±0.9
31.5±1.1
31.5±1.0
31.4±1.0
31.6±1.1

a

No statistical difference between baseline PbtO2 between all groups. b
Both CO-exposed showed significant PbtO2 decreases compared to sham
groups (p<.0001). c No statistical difference between sham groups at Time
30. d B12r significantly increased PbtO2 compared to CO-Vehicle (p<.01). e
p<.0001 compared to CO-Vehicle f No significant difference between COB12r and sham groups. g p<.0001 compared to sham groups.

Table 4 – Summary Statistical Data for PbtO2 analysis.
Effect	
  
Rx	
  
Time	
  
Treatment*Time	
  

DF	
  

Den	
  DF	
  
3	
  
18	
  
54	
  

15.8	
  
431	
  
374	
  

F-‐Value	
  

Pr>F	
  

248.94	
   <.0001	
  
56.14	
   <.0002	
  
22.56	
   <.0003	
  

F-Values calculated using SAS™ Type 3 Tests of Fixed Effects Analysis of
Variance. Inter-group significance was calculated using paired Student’s t-tests
with p<.05 considered significant.

50

20$

AA
10$

0$

% Baseline Change

!10$

CO+B12r$

!20$

CO+Vehicle$
Sham+B12r$
Sham+Vehicle$

!30$

!40$

!50$

B12r or Vehicle
Rx

!60$

CO or Sham Exposure

Post-Exposure Monitoring

!70$
0$

5$

10$

15$

20$

25$

30$

35$

40$

45$

50$

55$

60$

65$

70$

75$

80$

85$

90$

Time (min)

40"

B

35"

B

30"

PbO2 (mmHg)

25"

CO+Vehicle (n=10)

20"

CO+B12r (n=10)
Sham+Vehicle (n=5)
Sham+B12r (n=5)

15"

10"

B12r or Vehicle
Rx
5"

CO or Sham Exposure

Post-Exposure Monitoring

0"
0"

5"

10"

15"

20"

25"

30"

35"

40"

45"

50"

55"

60"

65"

70"

75"

80"

85"

90"

Time (min)

Figure 10: Mean PbtO2 Values and Standard Deviations of the Mean Over Time. (A)
Mean PbtO2 values and standard deviations of the mean. Sham-exposed groups remained
stable with no significant changes between Time 0 and Time 90 (p>0.1). B12r rapidly
rescued PbtO2 in CO-poisoned rats compared to Vehicle-treated rats within 5 minutes of
treatment (p<.0001). (B) Mean PbtO2 presented as percent change from baseline with
standard deviations.
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Figure 11: Individual PbtO2 Trajectories by Experimental Groups. (A) COB12r, n=10 (on previous page); (B) CO-Vehicle, n=10 (on previous page); (C)
Sham-B12r, n=5 (on previous page); (D) Sham-Vehicle, n=5.
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3.2 Mean Arterial Pressure Results
Blood pressure was recorded continuously during the procedure. Mean arterial
pressure for each subject was calculated from a 30-second sample of the continuous
recording taken at five-minute intervals to correspond with PbtO2 and respiration rate
recordings. These data were then averaged with standard deviations calculated (Table
5) and plotted against time (Figure 12A). Subject data was again normalized for
individual baselines and presented as percent change from baseline with standard
deviations (Figure 12B). Because these data were manipulated multiple times to
produce single mean values, individual subject trajectories by experimental group are
presented in in Figures 13A-D.
Statistical analysis was again performed using SAS™ software Type 3 Tests of
Fixed Effects ANOVA, which was felt to be more appropriate than standard two-way
ANOVA. Inter-group significance calculations at relevant time points were carried out
using paired Student’s t-tests in order to avoid the inherent increased risk of falsely
significant differences associated with use of population-derived means in variance
analysis. Summary statistical data and relevant inter-group comparisons are given in
Table 4. Reported F-Values indicate significant effect on PbtO2 over time and between
groups (F=248.94, p<.0001; F=56.14, p<.0001).
There was no difference in mean MAP between groups at the start of the
procedure (p>0.7). Profound hypotension (46.2±1.9 and 45.4±2.0 mmHg) was seen at
the end of CO exposure in CO-B12r and CO-Vehicle groups respectively (p<.0001
compared to shams, p>0.77 between CO-exposed groups). The individual MAP
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trajectories during CO exposure varied widely, however there were noticeable patterns.
Figures 12A and 12B demonstrate that some subjects demonstrated rapid
decompensation within 15 minutes in an almost exponential-like fashion. Others were
able to compensate adequately for 15 minutes before MAP dropped below 70mmHg.
Sham-exposed rats did not demonstrate any changes during sham exposure (p>0.9).
Cessation of CO exposure caused an immediate upward MAP trend in both COexposed groups. The CO-B12r group exhibited a small but significant increase in MAP
10 minutes after treatment that lasted for approximately 10 minutes (p<.05 compared to
CO-Vehicle). MAP recovery in vehicle-treated rats was significantly slower and
remained significantly lower than both sham-exposed groups by end of monitoring
(p<.001). There was no significant difference between sham groups and CO-B12r rats
at Time 90 (p>0.6). Administration of B12r to Sham-exposed rats caused a significant
transient MAP increase (89.6±3.4 to 98.5±2.3 mmHg) that lasted for 25 minutes
(p<.0001). Vehicle administration did not affect MAP of Sham-exposed rats (p>0.2
compared to baseline).
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Table 5: Mean MAP Values and Standard Deviations of the Mean
CO-B12r

0

88.2±3.2

5

82.7±6.6

83.8±4.9

90.1±3.1

88.5±1.9

10

76.9±11.2

74.2±9.7

89.7±2.5

89.9±1.6

15

64.4±13.1

63.0±12.0

89.3±2.3

90.5±1.3

20

51.7±9.5

53.6±8.8

88.9±2.1

89.7±1.7

25

46.8±4.2

30

46.2±1.9

35

62.2±9.7

40

73.8±7.9

45

77.1±8.3

a

CO-Vehicle
89.3±3.5

a

89.6±2.5

47.0±4.0
b

45.4±2.0
67.4±3.8

a

88.7±2.2
b

59.3±5.0
d

Sham-B12r

ShamVehicle

Time

d

89.6±3.4

89.4±2.4

98.5±2.3

c

89.4±1.5

92.7±2.3

87.7±1.3
e

77.7±7.9

76.2±6.2

93.0±2.7

55

79.2±2

78.41±7.0

92.1±4.5

88.4±3.4

60

80.9±6.4

79.1±7.9

91.3±3.9

90.1±1.8

65

82.5±6.6

79.1±6.9

91.3±2.6

89.4±1.3

70

83.4±5.9

79.8±6.7

90.8±2.6

89.5±1.7

75

85.4±6.3

80.4±6.6

89.3±1.4

89.2±0.6

80

87.0±5.6

80.3±5.7

89.5±2.5

88.5±1.1

85

87.2±6.7

89.2±3.2

88.7±1.5

90

87.7±5.3

80.7±5.0
80.8±4.15

e

b

89.5±2.2

50

e

a

89.2±1.5
b

95.1±3.4

73.4±5.2

89.0±2.5

88.6±2.7

a

88.5±2.0

e

89.0±2.4
b

No significant difference between groups at Time 0. No significant
difference between CO-exposed groups or between sham-exposed
groups. p<.0001 CO-exposed to sham-exposed. c Significant MAP
increase after B12r administration. p<.0001 compared to CO-Vehicle. d
B12r administration significantly increased MAP. p<.05 compared to COVehicle. e Indicates p<.05 between marked group at corresponding time
points.

Table 6 – Summary Statistical Data for MAP Analysis.

Effect	
  

DF	
  

Rx	
  
3	
  
Time	
  
18	
  
Treatment*Time	
   54	
  

Den	
  DF	
  

F-‐Value	
  

Pr>F	
  

22.8	
  
433	
  
359	
  

116.2	
  
38.01	
  
13.16	
  

<.0001	
  
<.0001	
  
<.0001	
  

F-Values calculated using SAS™ Type 3 Tests of Fixed Effects Analysis of Variance.
Inter-group significance was calculated using paired Student’s t-tests with p<.05
considered significant.
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Figure 12: Mean MAP and Standard Deviations of the Mean Over Time. (A) Mean
map and standard deviations of the mean. CO exposure caused similar profound
hypotension in CO-B12r and CO-Vehicle rats (p>0.7). MAP of sham-exposed groups
did not change (p>0.9). B12r caused significant transient MAP increases in both
treatment groups (p<.05). CO-B12r rats demonstrated significantly higher MAP 60
minutes after treatment that did not differ from sham-exposed groups (p<.001,
p>0.6). (B) Mean MAP and standard deviations presented as % change from
baseline.
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Figure 13: Individual MAP Trajectories by Experimental Group. CO-exposed
rats displayed marked hypotension with unique patterns of compensation.
Treatment with B12r caused a transient significant MAP increase in both groups
in comparison to their respective vehicle control (p<.05). (A) CO-B12r, n=10 (on
previous page); (B) CO-Vehicle, n=10 (on previous page); (C) Sham-B12r, n=5
(on previous page); (D) Sham-Vehicle, n=5.
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3.3 Arterial Blood Gas Results
Arterial blood samples were taken at the following experimental time points
marked in Figure 4: Time 0 (baseline), Time 30 (post-exposure), Time 50 (20 minutes
post-treatment) and Time 90 (final). Parameters analyzed included pH, pO2, PCO2,
HCO3-, ctHb, %COHb, and lactic acid. Values of %COHb were not recorded for rats
receiving B12r, as hydroxocobalamin interferes with absorbance spectroscopy and
provides unreliable data.203,204 Means of each parameter and standard deviations were
calculated (Table 7) and each parameter was analyzed using two-way ANOVA.
Statistical significance was calculated using the Fisher Least Square Difference test and
paired Student’s t-tests with p<.05 considered significant. Summary statistical data for
ANOVA of each parameter are presented in Table 8.
There were no differences in baseline (Time 0) arterial blood chemistry between
groups and all parameters were within normal published limits for anesthetized rats.205
Mean post-exposure %COHb in CO-B12r and CO-Vehicle groups was 58.4±5.6% and
60.1±3.6% (p<.0001 compared to shams). A significant increase in pO2 and decrease in
pCO2 was noted in both CO-exposed groups at Time 30 due to the compensatory
hyperventilation response to CO (p<.05 compared to baseline and shams). Lactate
levels increased in CO-B12r (1.0±0.2mM to 3.4±0.9mM, p<.0001) and CO-Vehicle
groups (1.0±0.2mM to 3.6±0.4mM, p<.0001) and a significant compensatory decrease
in HCO3- was seen in each group, indicating a compensated acidosis (p<.05). Although
some individual rats did demonstrate pH changes after exposure to CO, no statistically
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significant changes in pH were noted at any time in any of the 4 groups. There were no
significant changes in HCO3- or lactate in sham-exposed groups at any point.
At Time 50, pCO2 remained significantly lower in CO-B12r and HCO3- remained
significantly lower in both CO-exposed groups compared to shams (p<.05). Lactate
levels in CO-B12r and CO-Vehicle decreased; there were no differences between the
two groups. By Time 90, all parameters except lactate and %COHb showed no
statistical difference between groups. Again, no difference was seen in the rate of
lactate decrease between CO-B12r and CO-Vehicle rats. The %COHb decrease from
60.1±3.6 to 29.9±5.7 indicates an approximate COHb half-life of 60 minutes. Although
the analysis of Hb concentration (ctHb) was statistically significant over time and
between groups (F=5.96, F=34.79), all rats remained within normal ranges of ctHb and
this was attributed to minor surgical blood loss and individual ctHb between subjects
among the groups.
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Table 7: Mean ABG Parameter Values and Standard Deviations of the Mean
	
  
	
  
pH	
  (7.40±0.05)	
  
pO2	
  (95±14	
  mmHg)	
  
pCO2	
  (45±10mmHg)	
  
-‐
HCO3 	
  (25±3mEq)	
  
Hb	
  (11.5-‐16	
  mg/dL)	
  
%COHb	
  (1-‐3%)	
  
Lactate	
  (<1.5mM)	
  
	
  
	
  
pH	
  (7.40±0.05)	
  
pO2	
  (95±14	
  mmHg)	
  
pCO2	
  (45±10mmHg)	
  
-‐
HCO3 	
  (25±3mEq)	
  
Hb	
  (11.5-‐16	
  mg/dL)	
  
%COHb	
  (1-‐3%)	
  
Lactate	
  (<1.5mM)	
  
	
  
	
  
pH	
  (7.40±0.05)	
  
pO2	
  (95±14	
  mmHg)	
  
pCO2	
  (45±10mmHg)	
  
-‐
HCO3 	
  (25±3mEq)	
  
Hb	
  (11.5-‐16	
  mg/dL)	
  
%COHb	
  (1-‐3%)	
  
Lactate	
  (<1.5mM)	
  
	
  
	
  
pH	
  (7.40±0.05)	
  
pO2	
  (95±14	
  mmHg)	
  
pCO2	
  (45±10mmHg)	
  
-‐
HCO3 	
  (25±3mEq)	
  
Hb	
  (11.5-‐16	
  mg/dL)	
  
%COHb	
  (1-‐3%)	
  
Lactate	
  (<1.5mM)	
  

Time	
  0	
  
CO-‐B12r	
  

CO-‐Vehicle	
  

Sham-‐B12r	
  

Sham-‐Vehicle	
  

7.43±0.01	
  
	
  
89.9±3.3
40.5±4.4	
  
27.3±1.8	
  
13.4±0.3	
  
2.4±0.2	
  
1.0±0.2	
  

7.43±0.02	
  
91.2±6.5	
  
41.0±1.4	
  
26.5±1.3	
  
13.5±0.6	
  
2.4±0.2	
  
1.0±0.2	
  

7.43±0.02	
  
89.2±6.6	
  
41.6±2.7	
  
27.5±0.9	
  
13.8±0.6	
  
2.4±0.2	
  
0.9±0.2	
  

7.42±0.01	
  
91.8±3.8	
  
40.2±3.4	
  
25.9±1.5	
  
14.2±0.4	
  
2.4±0.1	
  
1.0±0.1	
  

Time	
  30	
  
CO-‐B12r	
  

CO-‐Vehicle	
  

Sham-‐B12r	
  

Sham-‐Vehicle	
  

7.42±0.04	
  
a	
  
99.9±4.9
b	
  
37.4±2.3
c	
  
24.6±2.0
13.3±0.4	
  
d	
  
58.4±5.6
d	
  
3.4±0.9

7.38±0.06	
  
a	
  
99.9±7.2
a	
  
36.6±3.8
a	
  
22.6±2.3
13.5±0.5	
  
d	
  
60.1±3.6
d	
  
3.6±0.4

7.43±0.10	
  
90.4±7.3	
  
41.4±2.5	
  
27.2±1.0	
  
13.7±1.0	
  
2.4±0.3	
  
1.1±0.2	
  

7.42±0.01	
  
90.6±3.1	
  
41.1±2.9	
  
24.9±2.2	
  
14.0±0.4	
  
2.2±0.2	
  
1.0±0.1	
  

Time	
  50	
  
CO-‐B12r	
  

CO-‐Vehicle	
  

Sham-‐B12r	
  

Sham-‐Vehicle	
  

7.42±0.03	
  
86.8±3.6	
  
a	
  
38.8±2.4
a	
  
23.8±2.6
13.2±0.3	
  
	
  
-‐-‐-‐-‐-‐-‐-‐-‐
c	
  
3.0±1.0

7.40±0.08	
  
85.7±3.9	
  
39.8±4.9	
  
a	
  
23.4±2.8
13.2±0.5	
  
d	
  
42.9±4.7
c	
  
2.9±0.9

7.42±0.02	
  
89.4±4.0	
  
42.1±2.1	
  
26.6±1.1	
  
13.8±0.7	
  
-‐-‐-‐-‐-‐-‐	
  
1.1±0.2	
  

7.42±0.02	
  
88.7±1.6	
  
40.9±1.9	
  
26.5±1.6	
  
13.8±0.2	
  
2.4±0.2	
  
1.0±0.1	
  

CO-‐B12r	
  

CO-‐Vehicle	
  

Sham-‐B12r	
  

Sham-‐Vehicle	
  

7.41±0.03	
  
88.8±3.9	
  
39.6±1.5	
  
25.9±2.3	
  
13.2±0.4	
  
	
  
-‐-‐-‐-‐-‐-‐-‐-‐
a	
  
1.9±0.7

7.43±0.3	
  
88.2±2.4	
  
40.6±3.6	
  
26.3±1.4	
  
13.2±0.4	
  
d	
  
29.9±5.7
a	
  
1.8±0.6

7.42±0.03	
  
88.1±6.8	
  
40.6±3.5	
  
26.0±1.1	
  
13.9±0.6	
  
-‐-‐-‐-‐-‐-‐-‐	
  
1.2±0.3	
  

7.42±0.01	
  
89.3±4.2	
  
39.5±2.8	
  
26.4±1.4	
  
13.9±0.2	
  
2.4±0.3	
  
1.0±0.1	
  

Time	
  90	
  

Normal murine reference ranges are given as well. Note the evidence of
compensatory hyperventilation (increased pO2 and decreased pCO2) and
compensated lactic acidosis in CO-exposed groups.
a

(p<.05), b (p<.01), c (p<.001), d (p<.0001) in comparison to sham groups.
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Table 8: Summary Statistical Data for ABG Parameter Analysis.
Parameter
pH
pO2
pCO2
HCO3Hb
COHb
Lac

Variable

F-Value

p

Time

15.8

0.35

Group

431

0.63

Time

8.01

0.01*

Group

0.4

0.39

Time

2.91

0.09

Group

2.72

0.11

Time

5.68

0.02*

Group

2.58

0.12

Time

5.82

0.02*

Group

34.79

<.0001*

Time

5.96

0.02*

Group

6.57

0.01*

Time

6.64

0.01*

Group

5.69

0.02*

Calculated for α=0.05, degrees of freedom (Time) = 18,
degrees of freedom (Group) = 3. Critical F-Value = 3.17. *
denotes statistical significance of p<.05.
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3.4 Respiratory Rate Results
Respiratory rate (RR) for each subject was measured every 5 minutes starting at
Time 0 by observing chest rise for 30 seconds and doubling the observed rate to obtain
respiration rate per minute. Means and standard deviations were then calculated (Table
11) and plotted against respective time points (Figure 14). Data were analyzed using
StaPlus Pro® two-way ANOVA (Table 10). Significance was calculated using the Fisher
Least Square Difference test and paired Student’s t-tests with p<.05 considered
significant.
Neither sham-exposed groups demonstrated any significant changes in
respiratory rate over time or between groups for the duration of the procedure. Both
groups exposed to CO demonstrated a significant exponential-like decrease in RR
during exposure compared to sham groups (p<.0001 at Time 30). This decrease in RR
was associated with an observed increase in tidal volume (TV) and appearance of a
Kussmaul-like respiration pattern. This could not be quantified, as TV was not
measured. However, the increase in pO2 and decrease in pCO2 indicate an overall
increase in minute volume (MV), which confirms that TV must have increased.
Cessation of CO exposure resulted in recovery to baseline RR and observed
decrease in TV to baseline within 40 minutes in both CO-B12r and CO-Vehicle groups.
The CO-B12r remained significantly lower than sham groups until Time 60; CO-Vehicle
groups showed no significant difference from sham groups by Time 40. No significant
difference in RR was noted between CO-B12r and CO-Vehicle groups after treatment,
however the CO-Vehicle group did exhibit an insignificant change of approximately 2

64
resp/min compared to CO-B12r. There were no significant differences between the 4
groups from Time 60 to procedural end.

Table 9 – Mean Respiratory Rate and Standard Deviations of the Mean
Time

CO-B12r

0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90

57±3
53±4
49±5a
48±4b
46±4b
45±3c
45±3c
49±3b
50±4a
52±3a
53±2a
52±3a
55±3
55±3
55±3
55±3
57±3
55±2
56±2

COVehicle
57±2
54±3
50±2a
48±3b
47±3b
45±3c
46±4c
50±4a
52±5
54±3
53±3a
54±4
54±4
54±3
55±3
56±3
56±3
56±2
57±3

ShamB12r
58±4
58±3
60±4
57±5
58±5
57±5
59±5
56±5
56±5
58±6
58±5
56±3
57±6
60±5
59±3
56±4
56±5
57±4
56±4

ShamVehicle
57±3
57±2
57±3
58±3
56±3
58±2
57±4
56±4
56±2
57±4
57±3
56±2
56±2
56±3
55±2
56±4
56±1
57±3
57±2

Rate decreased significantly in CO-exposed rats and returned to baseline
within 40 minutes.a (p<.05), b (p<.01), c (p<.001), in comparison to sham
groups.
Table 10 – Summary Statistical Data for Respiratory Rate Analysis
Variable

F-Value

p

Time

4.51

<.0001*

Group

23.98

*<.0001

Calculated for α=0.05, degrees of freedom (Time) = 18, degrees of
freedom (Group) = 3. Critical F-Value = 3.17. Asterisk denotes
statistical significance of p<.05.
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Figure 14 – Mean Respiratory Rate and Standard Deviations of the Mean Over Time. Shamexposed groups did not demonstrate significant RR changes. CO exposure caused marked RR
decreases in both CO-exposed groups.. There were no significant differences in the rates of RR
recovery between the two CO-exposed groups.
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DISCUSSION
4.1 CO Poisoning, Perfusion, & Oxygenation
The most significant and novel observation from this study was that exposure to
CO caused marked decreases in PbtO2 that were rapidly rescued by B12r treatment
(Figure 10, p<.0001). To the best of our knowledge, this is the first time that PbtO2 has
ever been evaluated in the context of CO exposure. Implicit to the pathology of CO
poisoning and the hypothesis of this study is the idea that PbtO2 values are indicative of
cerebral cellular oxygenation. That is, low values indicate hypoxia and high values
indicate adequate brain oxygenation. While the temptation exists to interpret the
decrease in PbtO2 as evidence of CO-mediated hypoxia, much of the current literature
argues against the hypoxic theory of CO poisoning.46,51,89,95,98 Extreme caution must
therefore be taken in interpretation of these data. Given the complicated, poorly
understood pathophysiology of CO poisoning and the limited number of physiological
parameters measured, elucidating the exact physiological mechanisms responsible for
all changes seen is not possible. The physiological basis of PbtO2, determinants of
PbtO2 changes, and the correlation to other physiological parameters must be first
considered in the context of published data on the complex pathophysiological
mechanisms of CO poisoning.
PbtO2 is a measurement of extracellular dissolved O2, and is believed to
represent the balance between oxygen supply and metabolic needs, although the exact
relation of PbtO2 to cerebral oxygen supply/demand and other physiological parameters
is still under discussion in the literature.199,206 Determination of PbtO2 depends on the
complex interactions of factors that determine O2 delivery such as CBF, MAP, O2
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content of the blood, proper dissociation of O2 from Hb, ventilation, and the fraction of
inhaled oxygen (FiO2) as well as cerebral metabolic demands.200,207 The amount of
oxygen delivered to the brain can be derived from the Fick equation and is the product
of CBF and arterial oxygen content (CaO2): 𝐷𝑂! = 𝐶𝐵𝐹×𝐶! 𝑂! , where CaO2 is equal to:
𝑐𝑡𝐻𝑏

!
!"

×1.36

!"!!
!"#

×𝑆! 𝑂! % + 0.0032𝑘𝑃𝑎×𝑃𝑎𝑂! (SaO2% = %O2Hb, PaO2=arterial pO2).

The formation of COHb and subsequent left-shift of the O2-Hb dissociation curve
creates a functional anemia and significantly reduces CaO2, which is the foundation of
the hypoxic theory of CO poisoning.41,46,62,76,89,150 A decrease in CaO2 should
theoretically lead to a corresponding decrease in PbtO2, however the brain exhibits an
exquisite ability to autoregulate CBF in order to meet metabolic demands.201,208,209 It has
been established that CO poisoning causes an immediate NO-mediated compensatory
CBF increase in both animals and humans that is capable of maintaining DO2 even as
%COHb approaches 30-50% or higher, depending on the study.76,89,97,105-111
Additionally, Rostenthal and colleagues examined PbtO2 changes in traumatic brain
injury patients and reported that PbtO2 primarily reflects diffusion of dissolved oxygen,
and is therefore not an ischemia monitor per se.150 However, Rosenthal’s study was
performed on patients with normal O2Hb saturation and a similar analysis on COpoisoned blood has yet to be performed in humans, which could yield conflicting results
as COHb formation drastically reduces CaO2. Based on this, we cannot conclude that
the PbtO2 decrease was related to COHb formation alone despite %COHb in CO-B12r
(58.4±5.6) and CO-Vehicle (60.1±3.6) groups being above 50%. Indeed, we can
conclude that brain tissue oxygen tension is not directly related to %COHb per se.
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The ability of the brain to autoregulate CBF is MAP-dependent. In humans and
rodents, autoregulatory capacity is lost when MAP is <60mmHg, at which point CBF
begins to vary linearly with MAP.207,209 In the rat, CBF decreases from 100mL/min/100g
tissue to 60mL/min/100g tissue when MAP decreases from 90mmHg to 50mmHg.209,210
In our study, CO-B12r and CO-Vehicle groups demonstrated significant decreases in
MAP from 88.2±3.2 to 46.2±1.9mmHg and 89.3±3.5 to 45.4±Hg, respectively (p<.0001
compared to controls). An examination of the correlation between mean PbtO2 and
MAP in the CO-B12r and CO-Vehicle groups during exposure shows a tight nonlinear
correlation. An sigmoidal relationship is seen between the two variables, and a linear
trend between MAP and PbtO2 was noted with MAP <80mmHg, which could indicate
that autoregulation of CBF was compromised during CO exposure when MAP dropped
below 80mmHg and that subsequent PbtO2 changes were MAP-dependent. Although
we did not measure CBF during this study and therefore cannot determine if
autoregulation of CBF was indeed compromised, PbtO2 shares a sigmoidal relationship
with regional CBF when normal autoregulatory mechanisms are present that becomes
linear when compromised in traumatic brain injury studies (r=0.74, r=0.66).199,211 A
recently published computational study modeled PbtO2 changes in relation to changes
in MAP and SaO2 states that manipulation of a single physiological variable is often
incapable of causing significant PbtO2 changes due to the ability of the brain to
autoregulate, however ischemia is predicted when two or more physiological
derangements are present.207 In our study, both MAP and SaO2 were markedly altered,
and could therefore result in ischemia.
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Figure 15: Correlation of PbtO2 and MAP During CO exposure. Sigmoidal correlation
of mean PbtO2/MAP during 30-minute CO exposure. Data presented as as mean
PbtO2/MAP for each group (trend lines) with paired individual subject observations.
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A swine study by Hempfill et al. evaluating PbtO2 changes associated with
varying hemodynamic parameters corroborates our hypothesis that the decrease in
MAP is at least partly responsible for the noted PbtO2 in this study. They reported a
strong sigmoidal correlation (r2=0.72) of PbtO2 with MAP when MAP is between
60mmHg and 150mmHg (Figure 16). According to his data, MAP values of 50
correlated to PbtO2 values between 10-20mmHg, which is concurrent with our PbtO2
data set.212 Given the striking similarities in data and the linear variability of PbtO2 with
MAP, it can be reasonably hypothesized that autoregulatory capacity was lost and that
hypotension was the significant contributing factor to our data.

Figure 16: Correlation of PbtO2 with MAP - Hemphill et al. Adapted from
“Carbon Dioxide Reactivity and Pressure Autoregulation of Brain Tissue” by
Hemphill et al. Neurosurgery (2001). 48(2):377-383. Copyright Wolters Kluwer.
Used with permission.
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However, hypotension was not the only pathological variable and our PbtO2 data
demonstrated the greatest rate of decrease within the first 10 minutes of exposure when
MAP appeared high enough to maintain autoregulation. Interpretation of this variance
from published data requires consideration of the relationship between PbtO2 to other
physiological parameters. Multiple studies have demonstrated that PbtO2 correlates
highly with SjvO2 values (r2=0.71,r2=0.69), which is a well-studied and understood
indicator of cerebral oxygen delivery and consumption.199,213,214 Decreases in SjvO2
correspond to an increase in oxygen uptake from capillaries, via an increase in cerebral
metabolism or decrease in DO2, both of which result in a subsequent increase in OER,
therefore causing decreased SjvO2.215–217 Multiple animal studies have reported
decreased SjvO2 during CO poisoning, which was believed to be the result of a
compensatory increase in OER.62,76,89 It is therefore possible that the initial rate of PbtO2
decrease seen in our data could reflect an increase in OER as a compensatory
mechanism to CO. Our PbtO2 data appear to decrease in an exponential fashion, and a
simple exponential regression line gives r2=0.87 and r2=0.83 for CO-B12r and COVehicle groups respectively. This exponential rate of decay could indicate approaching
a steady-state equilibrium between O2 delivery from poisoned blood and CMRO2. Even
in the presence of a decrease in cerebral metabolism and increase in CBF, a 60%
reduction in CaO2 (approximately 60% COHb) could still require a compensatory OER
increase, which would be recorded as a decrease in PbtO2 as long as autoregulation is
maintained. In order to confirm this, a detailed study on the cerebrovascular and PbtO2
responses to CO poisoning would be required.
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We must also take into account this study’s greatest limitation and confounding
variable: anesthesia. This procedure required general anesthesia, however measures
were taken to ensure that minimal anesthesia was used while maintaining experimental
consistency. All rats received 2.0% isoflurane balanced in 2500ppm CO in medical air
or medical air during exposure and monitoring. This is approximately equivalent to 1.3
MAC.218 Although widely used in our laboratory and in myriad veterinary practices,
isoflurane is not without adverse effects. Isoflurane is vasoactive, and dose-dependent
decreases in MAP are well documented with its use.219,220 When given at 2.0 MAC it is
known to cause autoregulation dysfunction.221,222 Hoffman et al. reported that isoflurane
does not affect autoregulation at 1.0 MAC.222 Strebel et al. reported delayed
autoregulatory function at 1.0 MAC and ablation of autoregulation at 1.5 MAC.221 A
study on canine hemodynamics under anesthesia reported a 20% decrease in Q at
1.1MAC (1.7%) and that this was dose dependent.223 Recent anesthesia studies on
rabbits and rats have both demonstrated that 2% isoflurane can also cause loss of
autoregulation and decreases in PbtO2.224,225 It was recognized in designing this
experiment that using baseline anesthesia as a control to evaluate the additive effects
of anesthesia and CO was an unavoidable necessity. We must then consider the
potential additive effects of combining CO and isoflurane. Very little literature exists on
the interactions between the two; the only relevant publishing found during a literature
search was a case study on a perioperative CO poisoning case that did not provide any
hemodynamic parameters.226 Isoflurane is a substrate of sGC and can competitively
inhibit CO at the active site, but the extent to which this happens is not known. But
despite the lack of literature on clinical interactions of CO and isoflurane, it can be
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reasonably inferred that exposing an isoflurane-anesthetized animal with potentially
unstable cerebral hemodynamics to 2500ppm CO could cause rapid decompensation
and total loss of autoregulation that would be reflected by a drop in PbtO2.
The possible impact of mitochondrial inhibition must also be considered. In vitro
studies and in vivo studies on humans and rats have demonstrated significant
reductions in CcO activity following acute CO poisoning.65,99,102,126 The ability of O2 to
dissociate from hemoglobin and diffuse into tissue depends on the presence of an
oxygen gradient between the capillary and surrounding tissue. The main driving force
behind this gradient continuous reduction of O2 to create ATP by mitochondria during
oxidative phosphorylation.200 If oxidative phosphorylation is uncoupled, the driving force
for oxygen diffusion is reduced, resulting in an increase of PbtO2. This was recently
demonstrated by Nielsen and colleagues using a swine model of cyanide poisoning,
which is an inhibitor of oxidative phosphorylation.227
Regardless of the mechanisms, our data do indicate signs of global ischemia
without the presence of hypoxia in CO-exposed rats. Lactic acid levels were significantly
elevated in both CO-exposed groups after exposure, although pH remained unchanged
(p<.0001). Normal blood pH during and following CO poisoning is well documented.76,80
All CO-exposed rats demonstrated a hyperventilation response during CO poisoning
that was noted by a significantly decreased RR and observed increase in TV (p<.001).
Arterial blood gas analysis confirms that although RR decreased, MV must have
increased substantially as pO2 increased and pCO2 decreased significantly (p<.05,
p<.01, respectively). Significant decreases in HCO3- were also seen (p<.001).
Hyperventilation is a well known compensatory mechanism demonstrated during CO

74
poisoning.76,77,82 Increases in MV via an increase in TV are characteristic of a central
chemoreceptor-mediated response to cerebral acidosis. Although arterial pH was
adequately compensated for by the hyperventilatory response-induced decrease in
pCO2 and HCO3-, CSF pH was not measured and can differ widely from blood pH.76
4.2 Post-Exposure & Treatment
The most profound finding of this study is the significant rescuing effect of B12r
on the noted decreases in PbtO2 (p<.0001 in comparison to CO-Vehicle rats). Previous
in vitro studies by Roderique et al. and Somera et al. indicated that B12r was capable of
reacting with Hb-bound CO and oxidizing it to CO2.191,193 Unfortunately, the analytical
methods available to our laboratory could not accurately quantify COHb in the presence
of B12r. The Radiometer® ABL 800 blood analyzer used for ABG analyses determines
%COHb using spectrophotoscopic methods, and the absorbance spectrum of
hydroxocobalamin interferes with this analysis, therefore post-treatment %COHb
readings were not deemed to be accurate.203,204 However, the respiratory rate data does
suggest that this mechanism might also be conserved in vivo.
The CO-B12r group exhibited a significantly decreased respiratory rate and
Kussmaul-like pattern of TV for 25 minutes after treatment in comparison to shamexposed groups, whereas the CO-Vehicle group was not statistically different from
sham-exposed groups within 10 minutes of treatment, except for the noted difference at
Time 50 (p<.05). If B12r is truly oxidizing CO to CO2, this retained respiratory pattern
could be a compensatory mechanism to offgas the produced CO2. However, no related
increase in pCO2 or other blood chemistry changes were noted in CO-B12r rats after
treatment. The lack of significant differences in ABG parameters is clinically significant
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as it highlights the safety of OHCbl and AA in high doses. It also indicates that B12r
does not cause any substantial increases in pCO2 that could result in acidosis.
Both B12-r treated rats demonstrated significant MAP increases within 5-10
minutes after treatment (p<.0001, CO-Vehicle; p<.05, CO-B12r). Hydroxocobalamin is a
powerful scavenger of the vasodilatory NO molecule and NOS inhibitor.183,184 Removal
of free NO from circulation and decreased NO production by NOS inhibition causes
vasoconstriction, thus increasing blood pressure. This vasopressor response to OHCbl
is well documented across species.185,187 While the NO-scavenging mechanisms of
B12r explain the transient MAP increase after treatment, our data indicate that this is
not the mechanism behind the PbtO2 rescue.
Reanalysis of the correlation between PbtO2 and MAP post-treatment (Figure
17) yield two distinct patterns of recovery between the CO-B12r and CO-Vehicle
groups. Ratio plots of both CO-exposed groups show long linear tails that correlate with
published findings that PbtO2 varies directly with CBF, and therefore MAP, when
autoregulation is compromised.212 However, the opposing increases and decreases of
the treatment group PbtO2/MAP ratios away from the original CO exposure trend line
cannot be explained by blood pressure changes alone, given that PbtO2 varies in a
sigmoidal fashion with MAP. Post-treatment CO-B12r PbtO2/MAP is shifted left from
the exposure trend line and demonstrates a clear sigmoidal pattern of PbtO2 recovery
in relation to MAP when MAP>70mmHg. CO-Vehicle post-treatment data shifted
horizontally to the right from the exposure trend line and also showed a sharp
ΔPbtO2/ΔMAP increase with MAP >70mmHg. Based on the ΔPbtO2/ΔMAP increase
seen in both groups at MAP >70mmHg and published data on rat autoregulation, this

76
very likely indicates recovery of CBF autoregulation in both groups when MAP
>70mmHg. Recovery of autoregulation would rapidly increase DO2 and therefore
theoretically associate with marked increases in the PbtO2/MAP ratio as PbtO2 rises in
relation to MAP before reaching a steady state plateau. Although CO-Vehicle group
mean MAP at Time 50 was 76.2±6.2mmHg, a resurgent increase in PbtO2 back to
baseline levels was not seen. This, along with the shifts of the post-treatment
PbtO2/MAP ratios are evidence that there are latent determinants of PbtO2 that cannot
be accounted for given the limited parameters measured during this study.
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Figure 17: Overlay of Pre- & Post-Treatment PbtO2/MAP. CO-B12r (red) shifted to
the left of the previous sigmoidal relation. CO-Vehicle (blue) PbtO2/MAP recovery
was marked by a right shift of PbtO2/MAP and increased ratio at MAP >80mmHg.
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Addition of PbtO2/MAP ratios from sham groups to the PbtO2/MAP ratio plot
yields a more complete understanding of the overall of the relation between these two
variables (Figure 18).
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Figure 18: Mean PbtO2/MAP for all Groups and Times. The sigmoidal relationship
between MAP and PbtO2 is clearly demonstrated by junction of the Sham-B12r and
CO-B12r ratio.

The junction of the Sham-B12r and CO-B12r PbtO2/MAP clearly, albeit somewhat
unorthodoxly, shows the lower end of the sigmoidal PbtO2/MAP relationship. Despite
the presence of a MAP great enough to sustain normal autoregulation, PbtO2 remained
decreased after CO exposure in CO-Vehicle rats.
Our data can only account for changes in PbtO2 and MAP, and we cannot draw
conclusions as to the states of other variables based on these. However, mechanistic
inferences can be made based on basic physiological concepts. The decrease of the
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CO-Vehicle PbtO2/MAP ratio may signify impaired cerebral oxygen delivery based on
the simplified Fick principle 𝐷𝑂! = 𝐶𝐵𝐹×𝐶! 𝑂! , where CBF is equal to the difference
between MAP and intracranial pressure. If PbtO2 is an indicator of cerebral perfusion,
then we can alter that equation to 𝑃𝑏𝑡𝑂! ~𝑀𝐴𝑃×𝐶! 𝑂! =

!"#!!
!"#

~𝐶! 𝑂! and infer that the

right shift and decrease in PbtO2/MAP ratio seen after CO exposure corresponds to
decreased CaO2, possibly due to COHb hypoxia or continued cerebrovascular
dysfunction. Decreases in CMRO2 have also been described in multiple CO studies,
which could also correlate to a sustained decrease in PbtO2.97
We could also boldly make the reverse assumption regarding the CO-B12r
group. That is, a leftward shift of the PbtO2/MAP ratio could indicate increased CaO2.
Assuming that the in vitro reactivity of B12r with COHb is conserved in vivo, we cannot
rule out that B12r may have reacted with COHb without further animal studies.
However, these inference are simple and do not take any other physiological
parameters or the myriad pathological mechanisms of CO into account.
4.3 Limitations & Sources of Error
The biggest confounding variable in this stud was the previously discussed and
unavoidable anesthetic requirement and use of isoflurane. Given the current data on the
cerebrovascular actions of 2% isoflurane and the compensatory CBF increase in CO
poisoning that is capable of maintaining DO2, it is likely that the loss of autoregulated
CBF indicated by was a product of the combined actions of the two gases and these
data may prove difficult to replicate in awake subjects during future studies. The Licox®
system itself is another possible source of human error. The sensitive tip on the CC1.R
probe is 1mm long and is prone to fluctuations if moved a fraction of a millimeter after
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equilibrating. Literature from Integra Neuroscience states that the Licox® system can
deliver accurate readings within 2 minutes, however we opted for a 30-minute
equilibration time to avoid artifact from any microtrauma caused during placement; it is
possible that some of the PbtO2 data was influenced by catheter insertion-related
microtrauma despite careful surgical technique. The arterial blood gas analysis data
from this study show stable lactate and pO2 levels through the duration of the
procedures and gives evidence of high quality surgical work. We were additionally
limited in our inability to analyze blood for %COHb after B12r exposure.
4.4 Future Directions
The results of this study desperately warrant repetition, as this is the first
documented evaluation of PbtO2 in carbon monoxide poisoning and the first glimpse
into the physiology of the potential antidote designed by Roderique et al.191 The effects
of CO poisoning are myriad, complex, and still poorly understoo.11,46,48,62,89,97,99,101,125
Future work with respect to this study should probe the interactions between PbtO2,
cerebral hemodynamics, and cerebral blood flow that occur during acute CO exposure
and following B12r administration using PbtO2 electrodes in combination with SjvO2 and
arterial oximetry, An experimental design not confounded by anesthesia would be
preferable, as isoflurane and other volatile inhaled anesthetics disrupt normal
cerebrovascular coupling even at 1.0 MAC or below.220–222,225 It would also be poignant
to determine how PbtO2 changes with varying concentrations and exposure times to
CO. Given that there is no correlation between %COHb and prognosis, PbtO2 could
become a potential prognostic indicator for severe CO poisoning or serve as the
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foundation for a standard set of criteria to determine severity of CO exposure based on
correlated changes in PbtO2.35,46,48,129,131
One of the most pressing questions with respect to B12r is whether or not is truly
is capable of reacting with COHb, which is deceivingly simple to answer as typical
spectrophotometric analytical techniques are invalidated by the presence of
OHCbl.203,204 Blood analysis via GC-MS is capable of analyzing %COHb in the
presence of OHCbl.228–230 If given access to suitable equipment, analysis of %COHb
changes with our without B12r treatment in a small animal model would be a simple to
perform.
4.5 Summary
Previous studies by Roderique et al. and Somera et al. have implicated a
reduced form of hydroxocobalamin (B12r) as a potential therapy for acute CO
poisoning. Based on their data, we aimed to characterize the acute effects of CO
poisoning on brain tissue oxygen tension (PbtO2), mean arterial pressure (MAP),
respiratory rate (RR), and arterial blood gas (ABG) chemistry. MAP was recorded
continuously, PbtO2 and RR recorded every 5 minutes, and ABG samples taken at
baseline, post-exposure, and at two time points 20 and 60 minutes after treatment.
PbtO2 was monitored via an oxygen- sensitive Licox® Clark-type electrode placed into
the primary somatosensory cortex of anesthetized rats using stereotaxic technique and
exposed them to 2500ppm CO in medical air or medical air, both mixed with 2%
isoflurane to maintain sedation. Additional parameters measured included MAP,
respiratory rate, and serial blood gas analyses. Mean PbtO2 decreased from
31.3±1.2mmHg to 18.3±1.0mmHg in the CO-B12r group (n=10) and from
31.2±0.7mmHg to 18.2±1.3mmHg in the CO-Vehicle group (n=10)(p<.0001). MAP
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decreased significantly in both CO-exposed groups as well, from 88.2±3.2mmHg to
46.2±1.9mmHg in CO-B12r and from 89.3±3.5mmHg to 45.4±2.0mmHg in CO-Vehicle
(p<.0001). Exposure to CO was associated with a significant decrease in respiratory
rate and observed increase in tidal volume. Significant compensated lactic acidosis was
seen after CO exposure with mean lactate >3mM in both CO-exposed groups (p<.001).
.Both sham-exposed groups (n=5) did not demonstrate any significant parameter
differences with any of the groups at baseline or during sham exposure to medical air.
Following 30 minute exposure protocol, rats were administered a randomly
assigned treatment of 100mg/kg B12r (50mg OHCbl + 50mg AA/mL) or equivalent
volume of normal saline and monitored for 60 minutes. Rats were then humanely
euthanized.
Administration of B12r to CO-poisoned rats had a profound rescuing effect on the
decrease in PbtO2; mean CO-B12r was significantly higher than the CO-Vehicle group
within 5 minutes (p<.01). A correlating and significant increase in MAP was seen as well
(p<.05). CO-B12r RR remained significantly below CO-Vehicle RR for 15 minutes after
treatment(p<.05). No significant differences were noted in ABG analysis between the
two CO-exposed groups. Administration of B12r to sham-exposed rats caused a
significant transient MAP increase as well.
4.6 Conclusions
We were able to successfully demonstrate and reproduce decreased PbtO2 in
the rat brain during exposure to CO. It is widely accepted that CO poisoning causes an
immediate, NO-mediated increase in CBF, and that this is capable of maintaining DO2
to the brain.89,95,98,104–107 Our PbtO2 data correlated highly to MAP in a sigmoidal
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manner above 70mmHg and linearly below 70mmHg, which is consistent with the
published relationship between PbtO2 and MAP.212 This relationship became linear
when MAP dropped below 70mm, which is the approximate lower MAP limit of rat
cerebral autoregulation, and is consistent with loss of cerebrovascular coupling.209,212
Our findings suggest that the decrease in PbtO2 seen during CO poisoning was
mediated by loss of cerebral vasomotor tone and autoregulation. Isoflurane may have
played a role in destabilizing CBF that was exacerbated by the NO/cGMP-mediated
vasodilation of CO and resulted in vascular collapse.221,222,225 However, the complex
pathology of CO must also be considered, making it difficult to draw conclusions based
on this one study. Our data warrant repetition in a more hemodynamically stable animal
model.
Recovery of PbtO2 showed two very unique trends between CO-B12r and COVehicle groups characterized by rapid PbtO2 recovery and respective increases and
decreases of the PbtO2/MAP ratio. We believe that the NO-scavenging and inhibitory
effects on NOS by B12r are partially responsible for this effect. However, blood
pressure alone cannot explain the difference in PbtO2 recovery trends as the COVehicle MAP means were high enough to sustain autoregulation. It is possible that the
difference in PbtO2/MAP ratio seen in the CO-Vehicle group was indicative of continued
vascular dysfunction and/or COHb hypoxia. Although bold, we also postulate that the
PbtO2/MAP increase associated with B12r administration could be the result of an
increased arterial oxygen capacity as a result of B12r treatment and reaction with
COHb. The only concrete conclusions that this author feels comfortable drawing are
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that this study absolutely warrants further related work, and that like with any exciting
study we are left with more questions than answers.
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